1
|
Paquin R, Lee KT, Reyes C, Byrd JK. Treatment of obstructive sleep apnea after chemoradiation therapy for advanced head and neck cancer. Int J Oral Maxillofac Surg 2024; 53:364-367. [PMID: 36990831 DOI: 10.1016/j.ijom.2023.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Revised: 02/27/2023] [Accepted: 03/13/2023] [Indexed: 03/29/2023]
Abstract
This report presents a case of worsening obstructive sleep apnea (OSA) post-chemoradiation therapy that improved significantly after placement of a hypoglossal nerve stimulator. The patient was a 66-year-old male, diagnosed with head and neck cancer, who experienced exacerbation of OSA after receiving chemoradiation. A hypoglossal nerve stimulator was placed, with minimal complications. The patient showed a significant improvement in OSA as exhibited by the reduction in apnea-hypopnea index. Hypoglossal nerve stimulator placement appears to be a potential treatment option for induced or worsened OSA, which is a known complication of head and neck cancer treatment. When considering treatment options, upper airway stimulation is indeed a possible method in patients who meet the recommended guideline criteria.
Collapse
Affiliation(s)
- R Paquin
- Department of Otolaryngology, Head and Neck Surgery, Augusta University, Augusta, Georgia, USA
| | - K T Lee
- Emory University, Atlanta, Georgia, USA.
| | - C Reyes
- Department of Otolaryngology, Head and Neck Surgery, Augusta University, Augusta, Georgia, USA
| | - J K Byrd
- Department of Otolaryngology, Head and Neck Surgery, Augusta University, Augusta, Georgia, USA
| |
Collapse
|
2
|
Gentien D, Saberi-Ansari E, Servant N, Jolly A, de la Grange P, Némati F, Liot G, Saule S, Teissandier A, Bourc'his D, Girard E, Wong J, Masliah-Planchon J, Narmanli E, Liu Y, Torun E, Goulancourt R, Rodrigues M, Gaudé LV, Reyes C, Bazire M, Chenegros T, Henry E, Rapinat A, Bohec M, Baulande S, M'kacher R, Jeandidier E, Nicolas A, Ciriello G, Margueron R, Decaudin D, Cassoux N, Piperno-Neumann S, Stern MH, Gibcus JH, Dekker J, Heard E, Roman-Roman S, Waterfall JJ. Multi-omics comparison of malignant and normal uveal melanocytes reveals molecular features of uveal melanoma. Cell Rep 2023; 42:113132. [PMID: 37708024 PMCID: PMC10598242 DOI: 10.1016/j.celrep.2023.113132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 07/10/2023] [Accepted: 08/30/2023] [Indexed: 09/16/2023] Open
Abstract
Uveal melanoma (UM) is a rare cancer resulting from the transformation of melanocytes in the uveal tract. Integrative analysis has identified four molecular and clinical subsets of UM. To improve our molecular understanding of UM, we performed extensive multi-omics characterization comparing two aggressive UM patient-derived xenograft models with normal choroidal melanocytes, including DNA optical mapping, specific histone modifications, and DNA topology analysis using Hi-C. Our gene expression and cytogenetic analyses suggest that genomic instability is a hallmark of UM. We also identified a recurrent deletion in the BAP1 promoter resulting in loss of expression and associated with high risk of metastases in UM patients. Hi-C revealed chromatin topology changes associated with the upregulation of PRAME, an independent prognostic biomarker in UM, and a potential therapeutic target. Our findings illustrate how multi-omics approaches can improve our understanding of tumorigenesis and reveal two distinct mechanisms of gene expression dysregulation in UM.
Collapse
Affiliation(s)
- David Gentien
- Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Genomics Platform, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France.
| | - Elnaz Saberi-Ansari
- Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; INSERM U830, Research Center, Institut Curie, PSL Research University, 75005 Paris, France
| | | | | | | | - Fariba Némati
- Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, 75248 Paris, France
| | - Géraldine Liot
- Institut Curie, PSL Research University, CNRS, INSERM, UMR3347, U1021, Orsay, France
| | - Simon Saule
- Institut Curie, PSL Research University, CNRS, INSERM, UMR3347, U1021, Orsay, France; Université Paris-Saclay Centre National de La Recherche Scientifique, UMR 3347, Unité 1021, Orsay, France
| | - Aurélie Teissandier
- Institut Curie, PSL Research University, Sorbonne University, INSERM U934, CNRS UMR 3215, 75005 Paris, France
| | - Deborah Bourc'his
- Institut Curie, PSL Research University, Sorbonne University, INSERM U934, CNRS UMR 3215, 75005 Paris, France
| | | | - Jennifer Wong
- Department of Diagnostic and Theranostic Molecular Pathology, Unit of Somatic Genetic, Hospital, Institut Curie, Paris, France
| | - Julien Masliah-Planchon
- Department of Diagnostic and Theranostic Molecular Pathology, Unit of Somatic Genetic, Hospital, Institut Curie, Paris, France
| | - Erkan Narmanli
- Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; INSERM U830, Research Center, Institut Curie, PSL Research University, 75005 Paris, France
| | - Yuanlong Liu
- Department of Computational Biology, University of Lausanne, Lausanne, Switzerland; Swiss Cancer Center Leman, Lausanne, Switzerland; Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - Emma Torun
- Institut Curie, PSL Research University, Sorbonne University, INSERM U934, CNRS UMR 3215, 75005 Paris, France
| | | | - Manuel Rodrigues
- Department of Medical Oncology, Institut Curie, PSL Research University, 75005 Paris, France; INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée par la Ligue Nationale Contre le Cancer, Department of Genetics, Institut Curie, PSL Research University, 75005 Paris, France
| | - Laure Villoing Gaudé
- Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Genomics Platform, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France
| | - Cécile Reyes
- Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Genomics Platform, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France
| | - Matéo Bazire
- Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Genomics Platform, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France
| | - Thomas Chenegros
- Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Genomics Platform, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France
| | - Emilie Henry
- Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Genomics Platform, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France
| | - Audrey Rapinat
- Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Genomics Platform, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France
| | - Mylene Bohec
- Institut Curie Genomics of Excellence (ICGex) Platform, Institut Curie Research Center, PSL Research University, Paris, France
| | - Sylvain Baulande
- Institut Curie Genomics of Excellence (ICGex) Platform, Institut Curie Research Center, PSL Research University, Paris, France
| | | | - Eric Jeandidier
- Laboratoire de Génétique, Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, Mulhouse, France
| | - André Nicolas
- Pathex, Institut Curie, PSL Research University, Paris, France
| | - Giovanni Ciriello
- Department of Computational Biology, University of Lausanne, Lausanne, Switzerland; Swiss Cancer Center Leman, Lausanne, Switzerland; Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - Raphael Margueron
- Institut Curie, PSL Research University, Sorbonne University, INSERM U934, CNRS UMR 3215, 75005 Paris, France
| | - Didier Decaudin
- Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, 75248 Paris, France
| | - Nathalie Cassoux
- Department of Medical Oncology, Institut Curie, PSL Research University, 75005 Paris, France; Department of Ocular Oncology, Faculty of Medicine, Institut Curie, Université de Paris Descartes, 75005 Paris, France
| | - Sophie Piperno-Neumann
- Department of Medical Oncology, Institut Curie, PSL Research University, 75005 Paris, France
| | - Marc-Henri Stern
- INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée par la Ligue Nationale Contre le Cancer, Department of Genetics, Institut Curie, PSL Research University, 75005 Paris, France
| | - Johan Harmen Gibcus
- Department of Systems Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA
| | - Job Dekker
- Howard Hughes Medical Institute, Department of Systems Biology, Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA
| | - Edith Heard
- Director's Unit, European Molecular Biology Laboratory, 69117 Heidelberg, Germany
| | - Sergio Roman-Roman
- Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France.
| | - Joshua J Waterfall
- Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; INSERM U830, Research Center, Institut Curie, PSL Research University, 75005 Paris, France.
| |
Collapse
|
3
|
Silina L, Dufour F, Rapinat A, Reyes C, Gentien D, Maksut F, Radvanyi F, Verrelle P, Bernard-Pierrot I, Mégnin-Chanet F. Tyro3 Targeting as a Radiosensitizing Strategy in Bladder Cancer through Cell Cycle Dysregulation. Int J Mol Sci 2022; 23:ijms23158671. [PMID: 35955805 PMCID: PMC9368768 DOI: 10.3390/ijms23158671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Revised: 07/26/2022] [Accepted: 08/01/2022] [Indexed: 12/04/2022] Open
Abstract
Bladder cancer is a common cancer; it is the tenth most common cancer in the world. Around one fourth of all diagnosed patients have muscle-invasive bladder cancer (MIBC), characterized by advanced tumors and which remains a lethal disease. The standard treatment for MIBC is the bladder removal by surgery. However, bladder-preserving alternatives are emerging by combining chemotherapy, radiotherapy and minimal surgery, aiming to increase the patient’s quality of life. The aim of the study was to improve these treatments by investigating a novel approach where in addition to radiotherapy, a receptor, TYRO3, a member of TAM receptor tyrosine kinase family known to be highly expressed on the bladder cancer cells and involved in the control of cell survival is targeted. For this, we evaluated the influence of TYRO3 expression levels on a colony or cell survival assays, DNA damage, γH2AX foci formation, gene expression profiling and cell cycle regulation, after radiation on different bladder cell models. We found that TYRO3 expression impacts the radiation response via the cell cycle dysregulation with noeffets on the DNA repair. Therefore, targeting TYRO3 is a promising sensitization marker that could be clinically employed in future treatments.
Collapse
Affiliation(s)
- Linda Silina
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, PSL Research University, 75005 Paris, France
- INSERM U 1196/CNRS UMR 9187, Paris-Saclay Research University, 91405 Orsay, France
- Institut Curie, Bat. 112, Rue H. Becquerel, 91405 Orsay, France
| | - Florent Dufour
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, PSL Research University, 75005 Paris, France
| | - Audrey Rapinat
- Genomics Platform, Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France
| | - Cécile Reyes
- Genomics Platform, Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France
| | - David Gentien
- Genomics Platform, Translational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France
| | - Fatlinda Maksut
- INSERM U 1196/CNRS UMR 9187, Paris-Saclay Research University, 91405 Orsay, France
- Institut Curie, Bat. 112, Rue H. Becquerel, 91405 Orsay, France
| | - François Radvanyi
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, PSL Research University, 75005 Paris, France
| | - Pierre Verrelle
- INSERM U 1196/CNRS UMR 9187, Paris-Saclay Research University, 91405 Orsay, France
- Institut Curie, Bat. 112, Rue H. Becquerel, 91405 Orsay, France
- Institut Curie-Hospital, Radiation Oncology Department, 75005 Paris, France
- Department of Radiation Oncology, Faculty of Medicine, Clermont Auvergne University, 63000 Clermont-Ferrand, France
| | - Isabelle Bernard-Pierrot
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, PSL Research University, 75005 Paris, France
| | - Frédérique Mégnin-Chanet
- INSERM U 1196/CNRS UMR 9187, Paris-Saclay Research University, 91405 Orsay, France
- Institut Curie, Bat. 112, Rue H. Becquerel, 91405 Orsay, France
- Correspondence:
| |
Collapse
|
4
|
Reyes C, Santana V, Arocha G, Martínez N, Almonte K. Prevalence of depressive symptoms and suicide risk among medical residents. Eur Psychiatry 2022. [PMCID: PMC9566957 DOI: 10.1192/j.eurpsy.2022.1412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Introduction Depression and suicide risk are disturbing issues within the medical community. In many countries, physician’s mental health is not a concern, due to the fact that many do not even consider medical staff as potential mental health patients. However, health care providers are an at risk population for phycological affliction due to their heavy workload. Objectives We aim to describe the prevalence of depressive symptoms and suicidal risk among medical residents from health centers of Santiago de los Caballeros, Dominican Republic. Methods A cross-sectional descriptive study was made, between the months of February and May 2021, using the Beck Depression Inventory II (BDI-2) and the Plutchick Suicidal Risk Scale. Results
There was a total population of 507 residents, where 231 completed the survey. Of these, 1 recanted his participation, and 14 were excluded according to the study’s criteria, resultingin a total of 217 residents. The overall prevalence of depressive symptoms was 24.9% and suicidal risk was 22.94%. Residents who worked in a private center had 3.83 times more risk of suffering depressive symptoms compared to those who belonged to the public sector. Furthermore, residents from Internal Medicine (39.5%) had a higher prevalence of depressive symptoms, and residents from Anesthesiology (42.2%) suffered a higher suicide risk compared to other medical residences. Conclusions A disturbing percentage of the medical residents suffer from depressive symptoms and suicidal risk. Therefore, residency programs should offer assistance to help prevent and manage mental health disorders. Disclosure No significant relationships.
Collapse
|
5
|
Suresh S, Huard S, Brisson A, Némati F, Dakroub R, Poulard C, Ye M, Martel E, Reyes C, Silvestre DC, Meseure D, Nicolas A, Gentien D, Fayyad-Kazan H, Le Romancer M, Decaudin D, Roman-Roman S, Dubois T. PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer. Cancers (Basel) 2022; 14:cancers14020306. [PMID: 35053470 PMCID: PMC8774276 DOI: 10.3390/cancers14020306] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 01/04/2022] [Accepted: 01/06/2022] [Indexed: 02/04/2023] Open
Abstract
Simple Summary Patients with triple-negative breast cancer (TNBC) respond well to chemotherapy initially but are prone to relapse. Searching for new therapeutic targets, we found that PRMT1 is highly expressed in TNBC tumor samples and is essential for breast cancer cell survival. Furthermore, this study proposes that targeting PRMT1 in combination with chemotherapies could improve the survival outcome of TNBC patients. Abstract Identifying new therapeutic strategies for triple-negative breast cancer (TNBC) patients is a priority as these patients are highly prone to relapse after chemotherapy. Here, we found that protein arginine methyltransferase 1 (PRMT1) is highly expressed in all breast cancer subtypes. PRMT1 depletion decreases cell survival by inducing DNA damage and apoptosis in various breast cancer cell lines. Transcriptomic analysis and chromatin immunoprecipitation revealed that PRMT1 regulates the epidermal growth factor receptor (EGFR) and the Wnt signaling pathways, reported to be activated in TNBC. PRMT1 enzymatic activity is also required to stimulate the canonical Wnt pathway. Type I PRMT inhibitors decrease breast cancer cell proliferation and show anti-tumor activity in a TNBC xenograft model. These inhibitors display synergistic interactions with some chemotherapies used to treat TNBC patients as well as erlotinib, an EGFR inhibitor. Therefore, targeting PRMT1 in combination with these chemotherapies may improve existing treatments for TNBC patients.
Collapse
Affiliation(s)
- Samyuktha Suresh
- Breast Cancer Biology Group, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France; (S.S.); (S.H.); (A.B.); (R.D.); (M.Y.); (D.C.S.)
| | - Solène Huard
- Breast Cancer Biology Group, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France; (S.S.); (S.H.); (A.B.); (R.D.); (M.Y.); (D.C.S.)
| | - Amélie Brisson
- Breast Cancer Biology Group, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France; (S.S.); (S.H.); (A.B.); (R.D.); (M.Y.); (D.C.S.)
| | - Fariba Némati
- Pre-Clinical Investigation Laboratory, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France; (F.N.); (D.D.)
| | - Rayan Dakroub
- Breast Cancer Biology Group, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France; (S.S.); (S.H.); (A.B.); (R.D.); (M.Y.); (D.C.S.)
- Laboratory of Cancer Biology and Molecular Immunology, Faculty of Sciences-I, Lebanese University, Hadath, Beirut 1003, Lebanon;
| | - Coralie Poulard
- Cancer Research Center of Lyon, CNRS UMR5286, Inserm U1052, University of Lyon, 69000 Lyon, France; (C.P.); (M.L.R.)
| | - Mengliang Ye
- Breast Cancer Biology Group, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France; (S.S.); (S.H.); (A.B.); (R.D.); (M.Y.); (D.C.S.)
| | - Elise Martel
- Platform of Experimental Pathology, Department of Diagnostic and Theranostic Medicine, Institut Curie-Hospital, 75005 Paris, France; (E.M.); (D.M.); (A.N.)
| | - Cécile Reyes
- Genomics Core Facility, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France; (C.R.); (D.G.)
| | - David C. Silvestre
- Breast Cancer Biology Group, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France; (S.S.); (S.H.); (A.B.); (R.D.); (M.Y.); (D.C.S.)
| | - Didier Meseure
- Platform of Experimental Pathology, Department of Diagnostic and Theranostic Medicine, Institut Curie-Hospital, 75005 Paris, France; (E.M.); (D.M.); (A.N.)
| | - André Nicolas
- Platform of Experimental Pathology, Department of Diagnostic and Theranostic Medicine, Institut Curie-Hospital, 75005 Paris, France; (E.M.); (D.M.); (A.N.)
| | - David Gentien
- Genomics Core Facility, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France; (C.R.); (D.G.)
| | - Hussein Fayyad-Kazan
- Laboratory of Cancer Biology and Molecular Immunology, Faculty of Sciences-I, Lebanese University, Hadath, Beirut 1003, Lebanon;
| | - Muriel Le Romancer
- Cancer Research Center of Lyon, CNRS UMR5286, Inserm U1052, University of Lyon, 69000 Lyon, France; (C.P.); (M.L.R.)
| | - Didier Decaudin
- Pre-Clinical Investigation Laboratory, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France; (F.N.); (D.D.)
| | - Sergio Roman-Roman
- Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France;
| | - Thierry Dubois
- Breast Cancer Biology Group, Translational Research Department, Institut Curie-PSL Research University, 75005 Paris, France; (S.S.); (S.H.); (A.B.); (R.D.); (M.Y.); (D.C.S.)
- Correspondence: ; Tel.: +33-1-56246250
| |
Collapse
|
6
|
Saghatchian M, Abehsera M, Yamgnane A, Geyl C, Gauthier E, Hélin V, Bazire M, Villoing-Gaudé L, Reyes C, Gentien D, Golmard L, Stoppa-Lyonnet D. Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic. Breast Cancer Res Treat 2022; 192:375-383. [PMID: 34994879 PMCID: PMC8739506 DOI: 10.1007/s10549-021-06445-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Accepted: 11/08/2021] [Indexed: 11/02/2022]
Abstract
PURPOSE A personalized approach to prevention and early detection based on known risk factors should contribute to early diagnosis and treatment of breast cancer. We initiated a risk assessment clinic for all women wishing to undergo an individual breast cancer risk assessment. METHODS Women underwent a complete breast cancer assessment including a questionnaire, mammogram with evaluation of breast density, collection of saliva sample, consultation with a radiologist, and a breast cancer specialist. Women aged 40 or older, with 0 or 1 first-degree relative with breast cancer diagnosed after the age of 40 were eligible for risk assessment using MammoRisk, a machine learning-based tool that provides an individual 5-year estimated risk of developing breast cancer based on the patient's clinical data and breast density, with or without polygenic risk scores (PRSs). DNA was extracted from saliva samples for genotyping of 76 single-nucleotide polymorphisms. The individual risk was communicated to the patient, with individualized screening and prevention recommendations. RESULTS A total of 290 women underwent breast cancer assessment, among which 196 women (68%) were eligible for risk assessment using MammoRisk (median age 52, range 40-72). When PRS was added to MammoRisk, 40% (n = 78) of patients were assigned a different risk category, with 28% (n = 55) of patients changing from intermediate to moderate or high risk. CONCLUSION Individual risk assessment is feasible in the general population. Screening recommendations could be given based on individual risk. The use of PRS changed the risk score and screening recommendations in 40% of women.
Collapse
Affiliation(s)
- Mahasti Saghatchian
- American Hospital of Paris, Neuilly-sur-Seine, France. .,Paris-Descartes University, Paris, France.
| | - Marc Abehsera
- American Hospital of Paris, Neuilly-sur-Seine, France
| | | | - Caroline Geyl
- American Hospital of Paris, Neuilly-sur-Seine, France
| | | | | | | | | | | | | | - Lisa Golmard
- INSERM U830 D.R.U.M. Team, Institut Curie Hospital, Paris-University, Paris, France
| | - Dominique Stoppa-Lyonnet
- Institut Curie, Paris, France.,INSERM U830 D.R.U.M. Team, Institut Curie Hospital, Paris-University, Paris, France
| |
Collapse
|
7
|
Hwang J, McDowell S, Cole B, Huber AR, Reyes C. Cytologic Analysis of a Glomus Tumor in the Left Second Toe: Case Report. Am J Clin Pathol 2021. [DOI: 10.1093/ajcp/aqab191.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction/Objective
Glomus bodies reside in the stratum reticularis of the dermis as well as in visceral organs. Their functions involve temperature and blood pressure regulation. The incidence of glomus tumors is approximately 1.5%, occur more frequently in women, and generally manifest during the third to fifth decade of life. A majority of glomus tumors are diagnosed by biopsy and excision. At least 19 case reports exist in the literature where glomus tumors are diagnosed by fine-needle aspiration (FNA). We add to this growing literature by discussing a case report involving the cytologic findings of an FNA-diagnosed glomus tumor.
Methods/Case Report
A 66-year-old female presented with left second toe pain for 41 years but worsening in the past several months. Physical exam revealed 5/5 muscle strength in her toes without loss of sensation. There was no edema, erythema, nor ecchymosis. Pain was notably out of proportion when palpating her second nailbed. Magnetic resonance imaging (MRI) with contrast was performed revealing a 1.1 x 1.0 x 0.9 cm circumscribed, ovoid mass involving the dorsal aspect of the second toe distal phalanx along its dorsal margin (Figure 1). The patient underwent fine needle aspiration and biopsy. Cytologic findings included clusters of uniform cells with round to oval nuclei and scant cytoplasm. There was spindling of cells noted in some of the clusters. Cells were surrounded by thick wisps of magenta colored myxoid material reminiscent of a pleomorphic adenoma (Figure 2). Biopsy showed uniform cells surrounding capillaries. Immunohistochemistry performed on the biopsy showed that lesional cells were positive for alpha-smooth muscle actin (SMA). A diagnosis of glomus tumor was made. Amputation was performed with clear margins.
Results (if a Case Study enter NA)
NA
Conclusion
Glomus tumor is a rare tumor that is usually diagnosed on biopsy; however, it has distinct cytologic features that can aid in its diagnosis on fine needle aspirations.
Collapse
Affiliation(s)
- J Hwang
- Pathology, Brooke Army Medical Center, San Antonio, Texas, UNITED STATES
| | - S McDowell
- Department of Orthopaedics, University of Rochester School of Medicine & Dentistry, Rochester, New York, UNITED STATES
| | - B Cole
- Diagnostic Radiology, Ide Imaging Partners, Rochester, New York, UNITED STATES
| | - A R Huber
- Pathology & Laboratory Medicine, University of Rochester School of Medicine & Dentistry, Rochester, New York, UNITED STATES
| | - C Reyes
- Pathology & Laboratory Medicine, University of Rochester School of Medicine & Dentistry, Rochester, New York, UNITED STATES
| |
Collapse
|
8
|
Sirab N, Drubay D, Maillé P, Popova T, Ngo C, Gentien D, Moktefi A, Soyeux-Porte P, Pelletier R, Reyes C, Henry E, Pouessel D, Vordos D, Lebret T, de Reyniès A, Paoletti X, Radvanyi F, Allory Y. Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer. J Pathol 2021; 256:108-118. [PMID: 34611919 DOI: 10.1002/path.5813] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2021] [Revised: 09/23/2021] [Accepted: 10/01/2021] [Indexed: 12/12/2022]
Abstract
Basal/squamous (Ba/Sq) subtype represents an intrinsic and robust group in the consensus molecular classification of muscle-invasive bladder cancer (MIBC), with poor outcome and controversial chemosensitivity. We aimed to investigate the spectrum of intratumor heterogeneity (ITH) in the Ba/Sq subtype. First, we validated a 29-gene NanoString CodeSet to predict the Ba/Sq subtype for FFPE samples. We identified heterogeneous Ba/Sq tumors in a series of 331 MIBC FFPE samples using dual GATA3/KRT5/6 immunohistochemistry (IHC). Heterogeneous regions with distinct immunostaining patterns were studied separately for gene expression using the 29-gene CodeSet, for mutations by targeted next-generation sequencing, and for copy number alteration (CNA) by microarray hybridization. Among 83 Ba/Sq tumors identified by GATA3/KRT5/6 dual staining, 19 tumors showed heterogeneity at the IHC level. In one third of the 19 cases, regions from the same tumor were classified in different distinct molecular subtypes. The mutational and CNA profiles confirmed the same clonal origin for IHC heterogeneous regions with possible subclonal evolution. Overall, two patterns of intratumoral heterogeneity (ITH) were observed in Ba/Sq tumors: low ITH (regions with distinct immunostaining, but common molecular subtype and shared CNA) or high ITH (regions with distinct immunostaining, molecular subtype, and CNA). These results showed multilayer heterogeneity in Ba/Sq MIBC. In view of personalized medicine, this heterogeneity adds complexity and should be taken into account for sampling procedures used for diagnosis and treatment choice. © 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Nanor Sirab
- Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France
| | - Damien Drubay
- Gustave Roussy, Service de Biostatistique et d'Epidémiologie, INSERM U1018, CESP, Université Paris-Saclay, Villejuif, France
| | - Pascale Maillé
- Department of Pathology, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Tatiana Popova
- Institut Curie, INSERM, U830, DNA Repair and Uveal Melanoma (D.R.U.M.) Team, Paris, France
| | - Carine Ngo
- Université Paris-Est, U955 INSERM, Institut Mondor de Recherche Biomédicale, Créteil, France
| | - David Gentien
- Institut Curie, Translational Research Department, Genomic Platform, PSL Research University, Paris, France
| | - Anissa Moktefi
- Department of Pathology, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Pascale Soyeux-Porte
- Université Paris-Est, U955 INSERM, Institut Mondor de Recherche Biomédicale, Créteil, France
| | - Romain Pelletier
- Department of Pathology, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Cécile Reyes
- Institut Curie, Translational Research Department, Genomic Platform, PSL Research University, Paris, France
| | - Emilie Henry
- Institut Curie, Translational Research Department, Genomic Platform, PSL Research University, Paris, France
| | - Damien Pouessel
- Department of Medical Oncology, Institut Universitaire du Cancer Oncopole de Toulouse, Toulouse, France
| | - Dimitri Vordos
- Department of Urology, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Thierry Lebret
- Department of Urology, Hôpital Foch, Suresnes, France.,Université de Versailles-Saint-Quentin-en-Yvelines, UFR Santé Simone Veil, Guyancourt, France
| | - Aurélien de Reyniès
- Ligue Nationale Contre Le Cancer, Cartes D'Identité Des Tumeurs Program, Paris, France
| | - Xavier Paoletti
- Université de Versailles-Saint-Quentin-en-Yvelines, UFR Santé Simone Veil, Guyancourt, France.,Institut Curie, INSERM, U900, Statistical Methods for Precision Medicine (StaMPM), Saint-Cloud, France
| | - François Radvanyi
- Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France
| | - Yves Allory
- Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France.,Université de Versailles-Saint-Quentin-en-Yvelines, UFR Santé Simone Veil, Guyancourt, France.,Department of Pathology, Institut Curie, Saint-Cloud, France
| |
Collapse
|
9
|
Bièche I, Coussy F, El-Botty R, Vacher S, Château-Joubert S, Dahmani A, Montaudon E, Reyes C, Gentien D, Reyal F, Ricci F, Nicolas A, Marchio C, Vincent-Salomon A, Laé M, Marangoni E. HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast. J Hematol Oncol 2021; 14:143. [PMID: 34496925 PMCID: PMC8424935 DOI: 10.1186/s13045-021-01158-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Accepted: 08/30/2021] [Indexed: 11/29/2022] Open
Abstract
Malignant adenomyoepithelioma (AME) of the breast is an exceptionally rare form of breast cancer, with a significant metastatic potential. Chemotherapy has been used in the management of advanced AME patients, however the majority of treatments are not effective. Recent studies report recurrent mutations in the HRAS Q61 hotspot in small series of AMEs, but there are no preclinical or clinical data showing H-Ras protein as a potential therapeutic target in malignant AMEs. We performed targeted sequencing of tumours’ samples from new series of 13 AMEs, including 9 benign and 4 malignant forms. Samples from the breast tumour and the matched axillary metastasis of one malignant HRAS mutated AME were engrafted and two patient-derived xenografts (PDX) were established that reproduced the typical AME morphology. The metastasis-derived PDX was treated in vivo by different chemotherapies and a combination of MEK and BRAF inhibitors (trametinib and dabrafenib). All malignant AMEs presented a recurrent mutation in the HRAS G13R or G12S hotspot. Mutation of PIK3CA were found in both benign and malignant AMEs, while AKT1 mutations were restricted to benign AMEs. Treatment of the PDX by the MEK inhibitor trametinib, resulted in a marked anti-tumor activity, in contrast to the BRAF inhibitor and the different chemotherapies that were ineffective. Overall, these findings further expand on the genetic features of AMEs and suggest that patients carrying advanced HRAS-mutated AMEs could potentially be treated with MEK inhibitors.
Collapse
Affiliation(s)
- Ivan Bièche
- Genetics Department, Institut Curie, University of Paris, Paris, France.,Department of Diagnostic and Theranostic Medicine Paris, University of Paris, Paris, France.,INSERM U1016, Institut Cochin, Paris, France
| | - Florence Coussy
- Medical Oncology Department, Institut Curie, PSL Research University, Paris, France
| | - Rania El-Botty
- Translational Research Department, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France
| | - Sophie Vacher
- Genetics Department, Institut Curie, University of Paris, Paris, France.,Department of Diagnostic and Theranostic Medicine Paris, University of Paris, Paris, France
| | | | - Ahmed Dahmani
- Translational Research Department, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France
| | - Elodie Montaudon
- Translational Research Department, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France
| | - Cécile Reyes
- Translational Research Department, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France
| | - David Gentien
- Translational Research Department, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France
| | - Fabien Reyal
- Surgery Department, Institut Curie, PSL Research University, Paris, France.,INSERM U932, Immunity and Cancer, Institut Curie, Paris, France
| | - Francesco Ricci
- Medical Oncology Department, Institut Curie, PSL Research University, Paris, France
| | - André Nicolas
- Pathex, Institut Curie, PSL Research University, Paris, France
| | - Caterina Marchio
- Institut Curie, Pathology Department, PSL Research University, Paris, France.,Pathology Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.,Department of Medical Sciences, University of Turin, Turin, Italy
| | | | - Marick Laé
- Pathology Department, Centre Henri Becquerel, INSERM U1245, Université Rouen Normandie, Rouen, France
| | - Elisabetta Marangoni
- Translational Research Department, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France.
| |
Collapse
|
10
|
Suteau V, Seegers V, Munier M, Ben Boubaker R, Reyes C, Gentien D, Wery M, Croué A, Illouz F, Hamy A, Rodien P, Briet C. G Protein-coupled Receptors in Radioiodine-refractory Thyroid Cancer in the Era of Precision Medicine. J Clin Endocrinol Metab 2021; 106:2221-2232. [PMID: 34000025 DOI: 10.1210/clinem/dgab343] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/10/2021] [Indexed: 12/11/2022]
Abstract
CONTEXT Radioiodine-refractory thyroid cancers have poor outcomes and limited therapeutic options (tyrosine kinase inhibitors) due to transient efficacy and toxicity of treatments. Therefore, combinatorial treatments with new therapeutic approaches are needed. Many studies link G protein-coupled receptors (GPCRs) to cancer cell biology. OBJECTIVE To perform a specific atlas of GPCR expression in progressive and refractory thyroid cancer to identify potential targets among GPCRs aiming at drug repositioning. METHODS We analyzed samples from tumor and normal thyroid tissues from 17 patients with refractory thyroid cancer (12 papillary thyroid cancers [PTCs] and 5 follicular thyroid cancers [FTCs]). We assessed GPCR mRNA expression using NanoString technology with a custom panel of 371 GPCRs. The data were compared with public repositories and pharmacological databases to identify eligible drugs. The analysis of prognostic value of genes was also performed with TCGA datasets. RESULTS With our transcriptomic analysis, 4 receptors were found to be downregulated in FTC (VIPR1, ADGRL2/LPHN2, ADGRA3, and ADGRV1). In PTC, 24 receptors were deregulated, 7 of which were also identified by bioinformatics analyses of publicly available datasets on primary thyroid cancers (VIPR1, ADORA1, GPRC5B, P2RY8, GABBR2, CYSLTR2, and LPAR5). Among all the differentially expressed genes, 22 GPCRs are the target of approved drugs and some GPCRs are also associated with prognostic factors. DISCUSSION For the first time, we performed GPCR mRNA expression profiling in progressive and refractory thyroid cancers. These findings provide an opportunity to identify potential therapeutic targets for drug repositioning and precision medicine in radioiodine-refractory thyroid cancer.
Collapse
Affiliation(s)
- Valentine Suteau
- Département d'Endocrinologie-diabétologie nutrition, CHU Angers, Angers, France
- Faculty of Health, University of Angers (CHU Angers), Inserm 1083, CNRS 6015, MITOVASC, SFR ICAT, Angers, France
| | - Valérie Seegers
- Institut de Cancérologie de l'Ouest, Service de Biométrie, Angers, France
| | - Mathilde Munier
- Département d'Endocrinologie-diabétologie nutrition, CHU Angers, Angers, France
- Faculty of Health, University of Angers (CHU Angers), Inserm 1083, CNRS 6015, MITOVASC, SFR ICAT, Angers, France
- Centre de référence des maladies rares de la Thyroïde et des Récepteurs Hormonaux, Endo-ERN centre for rare endocrine diseases, Angers, France
| | - Rym Ben Boubaker
- Faculty of Health, University of Angers (CHU Angers), Inserm 1083, CNRS 6015, MITOVASC, SFR ICAT, Angers, France
| | - Cécile Reyes
- Institut Curie, Plateforme Génomique, Paris, France
| | | | - Méline Wery
- Faculty of Health, University of Angers (CHU Angers), SFR ICAT, Angers, France
| | - Anne Croué
- Département de Pathologie Cellulaire et Tissulaire, CHU Angers, Angers, France
| | - Frédéric Illouz
- Département d'Endocrinologie-diabétologie nutrition, CHU Angers, Angers, France
- Centre de référence des maladies rares de la Thyroïde et des Récepteurs Hormonaux, Endo-ERN centre for rare endocrine diseases, Angers, France
- Centre de compétence TUTHYREF, TUTHYREF Network, Angers, France
| | - Antoine Hamy
- Service de chirurgie viscérale, CHU d'Angers, Angers, France
| | - Patrice Rodien
- Département d'Endocrinologie-diabétologie nutrition, CHU Angers, Angers, France
- Faculty of Health, University of Angers (CHU Angers), Inserm 1083, CNRS 6015, MITOVASC, SFR ICAT, Angers, France
- Centre de référence des maladies rares de la Thyroïde et des Récepteurs Hormonaux, Endo-ERN centre for rare endocrine diseases, Angers, France
- Centre de compétence TUTHYREF, TUTHYREF Network, Angers, France
| | - Claire Briet
- Département d'Endocrinologie-diabétologie nutrition, CHU Angers, Angers, France
- Faculty of Health, University of Angers (CHU Angers), Inserm 1083, CNRS 6015, MITOVASC, SFR ICAT, Angers, France
- Centre de référence des maladies rares de la Thyroïde et des Récepteurs Hormonaux, Endo-ERN centre for rare endocrine diseases, Angers, France
- Centre de compétence TUTHYREF, TUTHYREF Network, Angers, France
| |
Collapse
|
11
|
Coussy F, El-Botty R, Château-Joubert S, Dahmani A, Montaudon E, Leboucher S, Morisset L, Painsec P, Sourd L, Huguet L, Nemati F, Servely JL, Larcher T, Vacher S, Briaux A, Reyes C, La Rosa P, Lucotte G, Popova T, Foidart P, Sounni NE, Noel A, Decaudin D, Fuhrmann L, Salomon A, Reyal F, Mueller C, Ter Brugge P, Jonkers J, Poupon MF, Stern MH, Bièche I, Pommier Y, Marangoni E. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. Sci Transl Med 2021; 12:12/531/eaax2625. [PMID: 32075943 DOI: 10.1126/scitranslmed.aax2625] [Citation(s) in RCA: 78] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2019] [Revised: 10/17/2019] [Accepted: 01/16/2020] [Indexed: 12/16/2022]
Abstract
Topoisomerase I (TOP1) inhibitors trap TOP1 cleavage complexes resulting in DNA double-strand breaks (DSBs) during replication, which are repaired by homologous recombination (HR). Triple-negative breast cancer (TNBC) could be eligible for TOP1 inhibitors given the considerable proportion of tumors with a defect in HR-mediated repair (BRCAness). The TOP1 inhibitor irinotecan was tested in 40 patient-derived xenografts (PDXs) of TNBC. BRCAness was determined with a single-nucleotide polymorphism (SNP) assay, and expression of Schlafen family member 11 (SLFN11) and retinoblastoma transcriptional corepressor 1 (RB1) was evaluated by real-time polymerase chain reaction (RT-PCR) and immunohistochemistry analyses. In addition, the combination of irinotecan and the ataxia telangiectasia and Rad3-related protein (ATR) inhibitor VE-822 was tested in SLFN11-negative PDXs, and two clinical non-camptothecin TOP1 inhibitors (LMP400 and LMP776) were tested. Thirty-eight percent of the TNBC models responded to irinotecan. BRCAness combined with high SLFN11 expression and RB1 loss identified highly sensitive tumors, consistent with the notion that deficiencies in cell cycle checkpoints and DNA repair result in high sensitivity to TOP1 inhibitors. Treatment by the ATR inhibitor VE-822 increased sensitivity to irinotecan in SLFN11-negative PDXs and abolished irinotecan-induced phosphorylation of checkpoint kinase 1 (CHK1). LMP400 (indotecan) and LMP776 (indimitecan) showed high antitumor activity in BRCA1-mutated or BRCAness-positive PDXs. Last, low SLFN11 expression was associated with poor survival in 250 patients with TNBC treated with anthracycline-based chemotherapy. In conclusion, a substantial proportion of TNBC respond to irinotecan. BRCAness, high SLFN11 expression, and RB1 loss are highly predictive of response to irinotecan and the clinical indenoisoquinoline TOP1 inhibitors.
Collapse
Affiliation(s)
- Florence Coussy
- Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France.,Medical Oncology Department, Institut Curie, PSL Research University, 75005 Paris, France.,Genetics Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Rania El-Botty
- Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France
| | | | - Ahmed Dahmani
- Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Elodie Montaudon
- Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Sophie Leboucher
- Institut Curie, PSL Research University, UMR3306, 91405 Orsay, France
| | - Ludivine Morisset
- Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Pierre Painsec
- Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Laura Sourd
- Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Léa Huguet
- Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Fariba Nemati
- Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Jean-Luc Servely
- BioPôle Alfort, Ecole Nationale Vétérinaire d'Alfort, 94704 Maisons Alfort, France.,INRA, PHASE Department, 37380 Nouzilly, France
| | | | - Sophie Vacher
- Genetics Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Adrien Briaux
- Genetics Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Cécile Reyes
- Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Philippe La Rosa
- INSERM, U900, 75005 Paris, France.,Institut Curie, PSL Research University, 75005 Paris, France
| | - Georges Lucotte
- INSERM, U900, 75005 Paris, France.,Institut Curie, PSL Research University, 75005 Paris, France
| | - Tatiana Popova
- Institut Curie, PSL Research University, 75005 Paris, France.,INSERM U830, 75005 Paris, France
| | - Pierre Foidart
- Laboratory of Tumor and Developmental Biology, Groupe Interdisciplinaire de Génoprotéomique Appliqué-Cancer (GIGA-Cancer), University of Liège, Liège 4000, Belgium
| | - Nor Eddine Sounni
- Laboratory of Tumor and Developmental Biology, Groupe Interdisciplinaire de Génoprotéomique Appliqué-Cancer (GIGA-Cancer), University of Liège, Liège 4000, Belgium
| | - Agnès Noel
- Laboratory of Tumor and Developmental Biology, Groupe Interdisciplinaire de Génoprotéomique Appliqué-Cancer (GIGA-Cancer), University of Liège, Liège 4000, Belgium
| | - Didier Decaudin
- Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France.,Medical Oncology Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Laetitia Fuhrmann
- Department of Pathology, Institut Curie, PSL Research University, 75005 Paris, France
| | - Anne Salomon
- Department of Pathology, Institut Curie, PSL Research University, 75005 Paris, France
| | - Fabien Reyal
- Surgery Department, Institut Curie, PSL Research University, 75005 Paris, France.,U932, Immunity and Cancer, INSERM, Institut Curie, 75005 Paris, France
| | - Christopher Mueller
- Queen's Cancer Research Institute, Queen's University, Kingston, ON K7L 3N6, Canada
| | - Petra Ter Brugge
- Division of Molecular Pathology and Cancer Genomics Centre Netherlands, Netherlands Cancer Institute, Amsterdam, 1066 CX, Netherlands
| | - Jos Jonkers
- Division of Molecular Pathology and Cancer Genomics Centre Netherlands, Netherlands Cancer Institute, Amsterdam, 1066 CX, Netherlands
| | - Marie-France Poupon
- Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Marc-Henri Stern
- Institut Curie, PSL Research University, 75005 Paris, France.,INSERM U830, 75005 Paris, France
| | - Ivan Bièche
- Genetics Department, Institut Curie, PSL Research University, 75005 Paris, France
| | - Yves Pommier
- Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
| | - Elisabetta Marangoni
- Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France.
| |
Collapse
|
12
|
Cros J, Théou-Anton N, Gounant V, Nicolle R, Reyes C, Humez S, Hescot S, Thomas de Montpréville V, Guyétant S, Scoazec JY, Guyard A, de Mestier L, Brosseau S, Mordant P, Castier Y, Gentien D, Ruszniewski P, Zalcman G, Couvelard A, Cazes A. Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology. Neuroendocrinology 2021; 111:158-169. [PMID: 32015233 DOI: 10.1159/000506292] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2019] [Accepted: 01/30/2020] [Indexed: 11/19/2022]
Abstract
INTRODUCTION High-grade lung neuroendocrine tumours with carcinoid morphology have been recently reported; they may represent the thoracic counterparts of grade 3 digestive neuroendocrine tumours. We aimed to study their genetic landscape including analysis of tumoral heterogeneity. METHODS Eleven patients with high-grade (>20% Ki-67 and/or >10 mitoses) lung neuroendocrine tumours with a carcinoid morphology were included. We analysed copy number variations, somatic mutations, and protein expression in 16 tumour samples (2 samples were available for 5 patients allowing us to study spatial and temporal heterogeneity). RESULTS Genomic patterns were heterogeneous ranging from "quiet" to tetraploid, heavily rearranged genomes. Oncogene mutations were rare and most genetic alterations targeted tumour suppressor genes. Chromosomes 11 (7/11), 3 (6/11), 13 (4/11), and 6-17 (3/11) were the most frequently lost. Altered tumour suppressor genes were common to both carcinoids and neuroendocrine carcinomas, involving different pathways including chromatin remodelling (KMT2A, ARID1A, SETD2, SMARCA2, BAP1, PBRM1, KAT6A), DNA repair (MEN1, POLQ, ATR, MLH1, ATM), cell cycle (RB1, TP53, CDKN2A), cell adhesion (LATS2, CTNNB1, GSK3B) and metabolism (VHL). Comparative spatial/temporal analyses confirmed that these tumours emerged from clones of lower aggressivity but revealed that they were genetically heterogeneous accumulating "neuroendocrine carcinoma-like" genetic alterations through progression such as TP53/RB1 alterations. CONCLUSION These data confirm the importance of chromatin remodelling genes in pulmonary carcinoids and highlight the potential role of TP53 and RB1 to drive the transformation in more aggressive high-grade tumours.
Collapse
Affiliation(s)
- Jerôme Cros
- Department of Pathology, ENETS Centre of Excellence, Beaujon-Bichat Hospitals, AP-HP, Paris, France
- Université de Paris, Paris, France
- INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France
| | | | - Valérie Gounant
- Department of Thoracic Oncology and Early Phase Clinical Trials Unit (CIC1425/CLIP2), Bichat Hospital, AP-HP, Paris, France
| | - Remy Nicolle
- Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France
| | - Cécile Reyes
- Institut Curie, PSL Research University, Translational Research Department, Genomics Platform, Paris, France
| | - Sarah Humez
- Department of Pathology, CHRU de Lille, Lille, France
| | - Ségolène Hescot
- Department of Nuclear Medicine, Institut Curie, CLCC, Saint-Cloud, France
| | | | | | - Jean-Yves Scoazec
- Department of Biopathology, Gustave Roussy Cancer Campus, Villejuif, France
- Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicêtre, France
| | - Alice Guyard
- Department of Pathology, ENETS Centre of Excellence, Beaujon-Bichat Hospitals, AP-HP, Paris, France
| | - Louis de Mestier
- Université de Paris, Paris, France
- INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France
- Department of Gastroenterology and Pancreatology, Beaujon Hospital, AP-HP, Clichy, France
| | - Solenn Brosseau
- Université de Paris, Paris, France
- Department of Thoracic Oncology and Early Phase Clinical Trials Unit (CIC1425/CLIP2), Bichat Hospital, AP-HP, Paris, France
| | - Pierre Mordant
- Université de Paris, Paris, France
- Department of Vascular and Thoracic Surgery, Bichat University Hospital, AP-HP, Université de Paris, Paris, France
| | - Yves Castier
- Université de Paris, Paris, France
- Department of Vascular and Thoracic Surgery, Bichat University Hospital, AP-HP, Université de Paris, Paris, France
| | - David Gentien
- Institut Curie, PSL Research University, Translational Research Department, Genomics Platform, Paris, France
| | - Philippe Ruszniewski
- Université de Paris, Paris, France
- INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France
- Department of Gastroenterology and Pancreatology, Beaujon Hospital, AP-HP, Clichy, France
| | - Gérard Zalcman
- Université de Paris, Paris, France
- Department of Thoracic Oncology and Early Phase Clinical Trials Unit (CIC1425/CLIP2), Bichat Hospital, AP-HP, Paris, France
| | - Anne Couvelard
- Department of Pathology, ENETS Centre of Excellence, Beaujon-Bichat Hospitals, AP-HP, Paris, France,
- Université de Paris, Paris, France,
- INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France,
| | - Aurélie Cazes
- Department of Pathology, ENETS Centre of Excellence, Beaujon-Bichat Hospitals, AP-HP, Paris, France
- Université de Paris, Paris, France
- INSERM U1152, Paris, France
| |
Collapse
|
13
|
Ali MS, Berencsi K, Marinier K, Deltour N, Perez-Guthann S, Pedersen L, Rijnbeek P, Lapi F, Simonetti M, Reyes C, Van der Lei J, Sturkenboom M, Prieto-Alhambra D. Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int 2020; 31:2425-2438. [PMID: 32757044 DOI: 10.1007/s00198-020-05580-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2020] [Accepted: 07/30/2020] [Indexed: 11/26/2022]
Abstract
UNLABELLED Strontium ranelate use, compared with oral bisphosphonates, is not associated with increased risk of AMI in patients with no contraindications for SR use. However, current strontium ranelate (compared with current bisphosphonate) appears associated with 25-30% excess risk of VTE and 35% excess risk of CVDeath. INTRODUCTION Evaluate the risk of cardiac and thromboembolic events among new users of SR and oral BPs without contraindications for SR. METHODS We conducted three multi-national, multi-database (Aarhus-Denmark, HSD-Italy, IPCI-Netherlands, SIDIAP-Spain, THIN-UK) case-control studies nested within a cohort of new users of SR/BP. We matched cases of acute myocardial infarction (AMI), venous thromboembolism (VTE), and cardiovascular death (CVDeath), up to 10 controls on gender, year of birth, index date, and country. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CIs) according to current SR vs current BP use and current vs past SR use, adjusting for potential confounders. Data were pooled using random effects meta-analysis. RESULTS No excess risk of AMI (5477 cases/54,674 controls) was found with current SR vs current BP (OR 0.89 (95%CI 0.70, 1.12)) nor with current vs past SR use (0.71(0.56, 0.91)). For VTE (5614 cases/6036 controls), an excess risk was found with current SR compared with current BP use, 1.24 (0.96, 1.61), and current vs past SR use, 1.30 (1.04, 1.62). For CVDeath (3019 cases/29,871 controls), an increased risk was seen with current SR vs current BP use, 1.35 (1.02, 1.80), but not with current vs past SR use (0.68 (0.48, 0.96)). CONCLUSION In patients without contraindications for SR, we found no evidence of an increased risk of AMI but a 25-30% excess risk of VTE and a 35% excess risk of CVDeath with current SR vs current BP users. This is despite a reduction in risk in CVDeath with current vs past SR users. The latter disparity could still be partially explained by cessation of preventative therapies in end-of-life or residual confounding by indication.
Collapse
Affiliation(s)
- M S Ali
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.
- Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel St, Bloomsbury, London, WC1E 7HT, UK.
| | - K Berencsi
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
- Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
| | - K Marinier
- Department of Pharmacoepidemiology and Real World Evidence, Servier, Suresnes, France
| | - N Deltour
- Department of Pharmacoepidemiology and Real World Evidence, Servier, Suresnes, France
| | | | - L Pedersen
- Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
| | - P Rijnbeek
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands
| | - F Lapi
- Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy
| | - M Simonetti
- Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy
| | - C Reyes
- GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute and CIBERFes, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain
| | - J Van der Lei
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands
| | - M Sturkenboom
- Julius Global Health, University Medical Center, Utrecht, Netherlands
| | - D Prieto-Alhambra
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
- GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute and CIBERFes, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain
| |
Collapse
|
14
|
Argiz L, Reyes C, Belmonte M, Franchi O, Campo R, Fra-Vázquez A, Val Del Río A, Mosquera-Corral A, Campos JL. Assessment of a fast method to predict the biochemical methane potential based on biodegradable COD obtained by fractionation respirometric tests. J Environ Manage 2020; 269:110695. [PMID: 32425161 DOI: 10.1016/j.jenvman.2020.110695] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 04/29/2020] [Accepted: 05/03/2020] [Indexed: 06/11/2023]
Abstract
The biochemical methane potential test (BMP) is the most common analytical technique to predict the performance of anaerobic digesters. However, this assay is time-consuming (from 20 to over than 100 days) and consequently impractical when it is necessary to obtain a quick result. Several methods are available for faster BMP prediction but, unfortunately, there is still a lack of a clear alternative. Current aerobic tests underestimate the BMP of substrates since they only detect the easily biodegradable COD. In this context, the potential of COD fractionation respirometric assays, which allow the determination of the particulate slowly biodegradable fraction, was evaluated here as an alternative to early predict the BMP of substrates. Seven different origin waste streams were tested and the anaerobically biodegraded organic matter (CODmet) was compared with the different COD fractions. When considering adapted microorganisms, the appropriate operational conditions and the required biodegradation time, the differences between the CODmet, determined through BMP tests, and the biodegradable COD (CODb) obtained by respirometry, were not significant (CODmet (57.8026 ± 21.2875) and CODb (55.6491 ± 21.3417), t (5) = 0.189, p = 0.853). Therefore, results suggest that the BMP of a substrate might be early predicted from its CODb in only few hours. This methodology was validated by the performance of an inter-laboratory studyconsidering four additional substrates.
Collapse
Affiliation(s)
- L Argiz
- CRETUS Institute, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Galicia, Spain.
| | - C Reyes
- Laboratorio de Biotecnología, Medio Ambiente e Ingeniería (LABMAI), Facultad de Ingeniería, Universidad de Playa Ancha, Avda. Leopoldo Carvallo 270, 2340000, Valparaíso, Chile
| | - M Belmonte
- Laboratorio de Biotecnología, Medio Ambiente e Ingeniería (LABMAI), Facultad de Ingeniería, Universidad de Playa Ancha, Avda. Leopoldo Carvallo 270, 2340000, Valparaíso, Chile
| | - O Franchi
- Facultad de Ingeniería y Ciencias, Universidad Adolfo Ibáñez, Avda. Padre Hurtado 750, Viña del Mar, Chile
| | - R Campo
- Dipartimento di Ingegneria Civile e Ambientale (DICEA), Università degli Studi Firenze, Via di Santa Marta, 3, 50139, Firenze, Italy
| | - A Fra-Vázquez
- CRETUS Institute, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Galicia, Spain
| | - A Val Del Río
- CRETUS Institute, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Galicia, Spain
| | - A Mosquera-Corral
- CRETUS Institute, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Galicia, Spain
| | - J L Campos
- Facultad de Ingeniería y Ciencias, Universidad Adolfo Ibáñez, Avda. Padre Hurtado 750, Viña del Mar, Chile
| |
Collapse
|
15
|
Montaudon E, Nikitorowicz-Buniak J, Sourd L, Morisset L, El Botty R, Huguet L, Dahmani A, Painsec P, Nemati F, Vacher S, Chemlali W, Masliah-Planchon J, Château-Joubert S, Rega C, Leal MF, Simigdala N, Pancholi S, Ribas R, Nicolas A, Meseure D, Vincent-Salomon A, Reyes C, Rapinat A, Gentien D, Larcher T, Bohec M, Baulande S, Bernard V, Decaudin D, Coussy F, Le Romancer M, Dutertre G, Tariq Z, Cottu P, Driouch K, Bièche I, Martin LA, Marangoni E. PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. Nat Commun 2020; 11:4053. [PMID: 32792481 PMCID: PMC7426966 DOI: 10.1038/s41467-020-17697-1] [Citation(s) in RCA: 68] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Accepted: 07/16/2020] [Indexed: 02/08/2023] Open
Abstract
A significant proportion of patients with oestrogen receptor (ER) positive breast cancers (BC) develop resistance to endocrine treatments (ET) and relapse with metastatic disease. Here we perform whole exome sequencing and gene expression analysis of matched primary breast tumours and bone metastasis-derived patient-derived xenografts (PDX). Transcriptomic analyses reveal enrichment of the G2/M checkpoint and up-regulation of Polo-like kinase 1 (PLK1) in PDX. PLK1 inhibition results in tumour shrinkage in highly proliferating CCND1-driven PDX, including different RB-positive PDX with acquired palbociclib resistance. Mechanistic studies in endocrine resistant cell lines, suggest an ER-independent function of PLK1 in regulating cell proliferation. Finally, in two independent clinical cohorts of ER positive BC, we find a strong association between high expression of PLK1 and a shorter metastases-free survival and poor response to anastrozole. In conclusion, our findings support clinical development of PLK1 inhibitors in patients with advanced CCND1-driven BC, including patients progressing on palbociclib treatment.
Collapse
Affiliation(s)
- Elodie Montaudon
- Translational Research Department, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | | | - Laura Sourd
- Translational Research Department, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - Ludivine Morisset
- Translational Research Department, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - Rania El Botty
- Translational Research Department, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - Léa Huguet
- Translational Research Department, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - Ahmed Dahmani
- Translational Research Department, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - Pierre Painsec
- Translational Research Department, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - Fariba Nemati
- Translational Research Department, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - Sophie Vacher
- Department of Genetics, Institut Curie, Paris, France
| | | | | | | | - Camilla Rega
- Institute of Cancer Research, 123 Old Brompton Road, SW7 3RP, London, UK
| | | | - Nikiana Simigdala
- Institute of Cancer Research, 123 Old Brompton Road, SW7 3RP, London, UK
| | - Sunil Pancholi
- Institute of Cancer Research, 123 Old Brompton Road, SW7 3RP, London, UK
| | - Ricardo Ribas
- Institute of Cancer Research, 123 Old Brompton Road, SW7 3RP, London, UK
| | - André Nicolas
- Department of Pathology, Institut Curie, Paris, France
| | | | | | - Cécile Reyes
- Translational Research Department, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - Audrey Rapinat
- Translational Research Department, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - David Gentien
- Translational Research Department, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - Thibaut Larcher
- INRA, APEX-PAnTher, Oniris, Rue De La Géraudière Cedex 3, 44322, Nantes, France
| | - Mylène Bohec
- Genomics of Excellence (ICGex) Platform, Institut Curie Research Center, Paris, France
| | - Sylvain Baulande
- Genomics of Excellence (ICGex) Platform, Institut Curie Research Center, Paris, France
| | | | - Didier Decaudin
- Translational Research Department, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
- Department of Medical Oncology, Institut Curie, Paris, France
| | - Florence Coussy
- Translational Research Department, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
- Department of Medical Oncology, Institut Curie, Paris, France
| | - Muriel Le Romancer
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, 28 Rue Laennec, 69000, Lyon, France
| | | | - Zakia Tariq
- Department of Genetics, Institut Curie, Paris, France
| | - Paul Cottu
- Department of Medical Oncology, Institut Curie, Paris, France
| | | | - Ivan Bièche
- Department of Genetics, Institut Curie, Paris, France
| | - Lesley-Ann Martin
- Institute of Cancer Research, 123 Old Brompton Road, SW7 3RP, London, UK
| | - Elisabetta Marangoni
- Translational Research Department, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France.
| |
Collapse
|
16
|
Xie J, Turkiewicz A, Collins G, Englund M, Strauss VY, Reyes C, Prieto-Alhambra D. OP0280 TEMPORAL TRENDS OF OPIOID USE AMONG INCIDENT OSTEOARTHRITIS PATIENTS IN CATALONIA, 2007-2016: A POPULATION-BASED COHORT STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3070] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Opioids are not recommended as first-line treatments for chronic pain management in osteoarthritis (OA), but recent data suggest they are commonly used in routine practice in North America and northern Europe.Objectives:To characterise the secular trends of opioid and strong opioids use in patients with incident OA from 2007 to 2016, and to explore the impact of patient characteristics on the use of opioid/s for OA.Methods:Data was obtained from the SIDIAP (The System for the Development of Research in Primary Care) database, which contains primary care records and pharmacy dispensing data for 80 % of the population in Catalonia (~ 6 million people). All persons aged 18 or older at the beginning of each calendar year with an incident OA diagnosis (including both peripheral and central joints) in the study period were included. Index date was the date of first OA diagnosis, and the observation period of opioid use was 1-year after index date. Opioids considered included codeine, tramadol, fentanyl, and morphine, with the latter three classified as strong opioids. The period prevalence of any opioid use was estimated in whole and sub-population stratified by sex, age, socio-economic status (U1 – U5, higher values of the indicator equivalent to deprivation) and residence area (rural/urban).Results:The 1-year prevalence of any opioid use among incident OA patients was around 15% from 2007 to 2012. After that, this figure grew by 10% approaching 25% in 2016. However, strong opioid use increased continuously to nearly triple, from 8% in 2007 to 20% in 2016. The different subgroups followed similar trends over time, with women 4% higher than men, oldest 10% higher than youngest, most deprived 6% higher than least deprived, and rural 1% higher than urban.Conclusion:The use of opioids (and especially strong opioids) has substantially increased in recent years among newly diagnosed OA patients in Catalonia. Our findings call for urgent action for safe opioid prescribing to avoid opioid abuse in OA patients especially amongst older women living in deprived areas.Figure 1.Trends of 1-year prevalence of opioid/s use among incident OA patients, whole and subgroup population.Disclosure of Interests:Junqing Xie: None declared, Aleksandra Turkiewicz: None declared, Gary Collins: None declared, Martin Englund Consultant of: Advisory Board 1 day (2019) Pfizer (Tanezumab)., Victoria Y Strauss: None declared, Carlen Reyes: None declared, Daniel Prieto-Alhambra Grant/research support from: Professor Prieto-Alhambra has received research Grants from AMGEN, UCB Biopharma and Les Laboratoires Servier, Consultant of: DPA’s department has received fees for consultancy services from UCB Biopharma, Speakers bureau: DPA’s department has received fees for speaker and advisory board membership services from Amgen
Collapse
|
17
|
Berencsi K, Sami A, Ali MS, Marinier K, Deltour N, Perez-Gutthann S, Pedersen L, Rijnbeek P, Van der Lei J, Lapi F, Simonetti M, Reyes C, Sturkenboom MCJM, Prieto-Alhambra D. Correction to: Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int 2020; 31:799. [PMID: 32025756 DOI: 10.1007/s00198-020-05314-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The original version of this article, published on 26 November 2019 contained a mistake.
Collapse
Affiliation(s)
- K Berencsi
- Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
| | - A Sami
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
| | - M S Ali
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
- Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
| | - K Marinier
- Department of Pharmacoepidemiology, Servier, Suresnes, France
| | - N Deltour
- Department of Pharmacoepidemiology, Servier, Suresnes, France
| | | | - L Pedersen
- Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
| | - P Rijnbeek
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - J Van der Lei
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - F Lapi
- Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy
| | - M Simonetti
- Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy
| | - C Reyes
- GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute and CIBERFes, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain
| | | | - D Prieto-Alhambra
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.
- GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute and CIBERFes, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain.
- Botnar Research Centre, Oxford, UK.
| |
Collapse
|
18
|
Berencsi K, Sami A, Ali MS, Marinier K, Deltour N, Perez-Gutthann S, Pedersen L, Rijnbeek P, Van der Lei J, Lapi F, Simonetti M, Reyes C, Sturkenboom MCJM, Prieto-Alhambra D. Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int 2020; 31:721-755. [PMID: 31696274 DOI: 10.1007/s00198-019-05181-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Accepted: 09/26/2019] [Indexed: 10/25/2022]
Abstract
INTRODUCTION In May 2013 and March 2014, the European Medicines Agency (EMA) issued two decisions restricting the use of strontium ranelate (SR). These risk minimisation measures (RMM) introduced new contraindications and limited the indications of SR therapy. The EMA required an assessment of the impact of RMMs on the use of SR in Europe. Methods design: multi-national, multi-database cohort Setting: electronic medical record databases based on hospital (Denmark) and primary care provenance (Italy, Spain, the Netherlands, UK). PARTICIPANTS the database source populations were included for population-based analyses, and SR users for patient-level analyses. INTERVENTION New RMMs included contraindications (ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, uncontrolled hypertension) and restricted SR indication to severe osteoporosis with initiation by experienced physician and not as first line anti-osteoporosis therapy. METHODS Prevalence and incidence rates of SR use in the population; prevalence of contraindications and restricted indications in SR users, plus 1-year therapy persistence. Drug use measures were calculated in three periods for comparison: reference (2004 to May 2013), transition (June 2013 to March 2014) and assessment (from April 2014 to end 2016). RESULTS The study population included 143 million person-years(PY) of follow-up and 76,141 incident episodes of SR treatment. Average monthly prevalence rates of SR use dropped by 86.4% from 62.6/10,000 PY (95 CI 62.4-62.9) in the reference to 8.5 (8.5-8.6) in the assessment period. Similarly, the incidence rate of SR use fell by 97.3% from 7.4/10,000 PY (7.4-7.4) to 0.2 (0.2-0.2) between the reference and assessment period. The prevalence of any contraindication decreased, whilst the prevalence of restricted indications increased in these periods. One-year persistence decreased in the assessment compared with reference period. CONCLUSIONS Our study demonstrates a substantial impact of the regulatory action to restrict use of SR in Europe: SR utilisation overall decreased strongly. The proportion of patients fulfilling the restricted indications, without contraindications, increased after the proposed RMMs.
Collapse
Affiliation(s)
- K Berencsi
- Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
| | - A Sami
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
| | - M S Ali
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
- Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
| | - K Marinier
- Department of Pharmacoepidemiology, Servier, Suresnes, France
| | - N Deltour
- Department of Pharmacoepidemiology, Servier, Suresnes, France
| | | | - L Pedersen
- Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
| | - P Rijnbeek
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - J Van der Lei
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - F Lapi
- Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy
| | - M Simonetti
- Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy
| | - C Reyes
- GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute and CIBERFes, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain
| | | | - D Prieto-Alhambra
- Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.
- GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute and CIBERFes, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain.
- Botnar Research Centre, Windmill Road, Oxford, OX37LD, UK.
| |
Collapse
|
19
|
Tebé C, Martínez-Laguna D, Carbonell-Abella C, Reyes C, Moreno V, Diez-Perez A, Collins GS, Prieto-Alhambra D. The association between type 2 diabetes mellitus, hip fracture, and post-hip fracture mortality: a multi-state cohort analysis. Osteoporos Int 2019; 30:2407-2415. [PMID: 31444526 DOI: 10.1007/s00198-019-05122-3] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Accepted: 07/31/2019] [Indexed: 12/20/2022]
Abstract
UNLABELLED Type 2 diabetes mellitus (T2DM) is associated with an excess risk of fractures and overall mortality. This study compared hip fracture and post-hip fracture mortality in T2DM and non-diabetic subjects. The salient findings are that subjects in T2DM are at higher risk of dying after suffering a hip fracture. INTRODUCTION Previous research suggests that individuals with T2DM are at an excess risk of both fractures and overall mortality, but their combined effect is unknown. Using multi-state cohort analyses, we estimate the association between T2DM and the transition to hip fracture, post-hip fracture mortality, and hip fracture-free all-cause death. METHODS Population-based cohort from Catalonia, Spain, including all individuals aged 65 to 80 years with a recorded diagnosis of T2DM on 1 January 2006; and non-T2DM matched (up to 2:1) by year of birth, gender, and primary care practice. RESULTS A total of 44,802 T2DM and 81,233 matched controls (53% women, mean age 72 years old) were followed for a median of 8 years: 23,818 died without fracturing and 3317 broke a hip, of whom 838 subsequently died. Adjusted HRs for hip fracture-free mortality were 1.32 (95% CI 1.28 to 1.37) for men and 1.72 (95% CI 1.65 to 1.79) for women. HRs for hip fracture were 1.24 (95% CI 1.08 to 1.43) and 1.48 (95% CI 1.36 to 1.60), whilst HRs for post-hip fracture mortality were 1.28 (95% CI 1.02 to 1.60) and 1.57 (95% CI 1.31 to 1.88) in men and women, respectively. CONCLUSION T2DM individuals are at increased risk of hip fracture, post-hip fracture mortality, and hip fracture-free death. After adjustment, T2DM men were at a 28% higher risk of dying after suffering a hip fracture and women had 57% excess risk of post-hip fracture mortality.
Collapse
Affiliation(s)
- C Tebé
- Biostatistics Unit at Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Spain
- Universitat de Barcelona, Barcelona, Spain
- Universitat Rovira i Virgili, Reus, Spain
| | - D Martínez-Laguna
- Atenció Primària Barcelona Ciutat, Institut Català de la Salut, Barcelona, Spain
- Grupo de Investigación GREMPAL, IDIAP Jordi Gol and CIBERFes, Universitat Autònoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain
| | - C Carbonell-Abella
- Atenció Primària Barcelona Ciutat, Institut Català de la Salut, Barcelona, Spain
- Grupo de Investigación GREMPAL, IDIAP Jordi Gol and CIBERFes, Universitat Autònoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain
| | - C Reyes
- Grupo de Investigación GREMPAL, IDIAP Jordi Gol and CIBERFes, Universitat Autònoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain
| | - V Moreno
- Biostatistics Unit at Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Spain
- Universitat de Barcelona, Barcelona, Spain
- Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, 08908, L'Hospitalet de Llobregat, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - A Diez-Perez
- Musculoskeletal Research Unit, IMIM-Hospital del Mar and CIBERFes, Universitat Autònoma de Barcelona and Instituto de Salud Carlos III, 08003, Barcelona, Spain
| | - G S Collins
- Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), University of Oxford, Windmill Road, Oxford, UK
| | - D Prieto-Alhambra
- Grupo de Investigación GREMPAL, IDIAP Jordi Gol and CIBERFes, Universitat Autònoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain.
- Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), University of Oxford, Windmill Road, Oxford, UK.
| |
Collapse
|
20
|
Bravo N, Klein K, Maulén G, Reyes C, Nasabun Flores V. PMH9 IMPACTO DE FACTORES SOCIOLOGICOS EN LA CALIDAD DE VIDA DE ADULTOS MAYORES INSTITUCIONALIZADOS CON DEPRESION: REVISION SISTEMATICA. Value Health Reg Issues 2019. [DOI: 10.1016/j.vhri.2019.08.290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Slembrouck L, Darrigues L, Laurent C, Mittempergher L, Delahaye LJ, Vanden Bempt I, Vander Borght S, Vliegen L, Sintubin P, Raynal V, Bohec M, Reyes C, Rapinat A, Helsmoortel C, Jongen L, Hoste G, Neven P, Wildiers H, Smeets A, Nevelsteen I, Punie K, Van Nieuwenhuysen E, Han S, Vincent Salomon A, Laas Faron E, Cynober T, Gentien D, Baulande S, Snel MH, Witteveen AT, Neijenhuis S, Glas AM, Reyal F, Floris G. Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris. Transl Oncol 2019; 12:1557-1565. [PMID: 31513983 PMCID: PMC6742807 DOI: 10.1016/j.tranon.2019.08.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2019] [Revised: 08/14/2019] [Accepted: 08/15/2019] [Indexed: 12/17/2022] Open
Abstract
A previously developed and centrally validated MammaPrint® (MP) and BluePrint® (BP) targeted RNA next-generation sequencing (NGS) kit was implemented and validated in two large academic European hospitals. Additionally, breast cancer molecular subtypes by MP and BP RNA sequencing were compared with immunohistochemistry (IHC). Patients with early breast cancer diagnosed at University Hospitals Leuven and Curie Institute Paris were prospectively included between September 2017 and January 2018. Formalin-fixed paraffin-embedded tissue sections were analyzed with MP and BP NGS technology at the beta sites and with both NGS and microarray technology at Agendia. Raw NGS data generated on Illumina MiSeq instruments at the beta sites were interpreted and compared with NGS and microarray data at Agendia. MP and BP NGS molecular subtypes were compared to surrogate IHC breast cancer subtypes. Equivalence of MP and BP indices was determined by Pearson's correlation coefficient. Acceptable limits were defined a priori, based on microarray data generated at Agendia between 2012 and 2016. The concordance, the Negative Percent Agreement and the Positive Percent Agreement were calculated based on the contingency tables and had to be equal to or higher than 90%. Out of 124 included samples, 48% were MP Low and 52% High Risk with microarray. Molecular subtypes were BP luminal, HER2 or basal in 82%, 8% and 10% respectively. Concordance between MP microarray at Agendia and MP NGS at the beta sites was 91.1%. Concordance of MP High and Low Risk classification between NGS at the beta sites and NGS at Agendia was 93.9%. Concordance of MP and BP molecular subtyping using NGS at the beta sites and microarray at Agendia was 89.5%. Concordance between MP and BP NGS subtyping, and IHC was 71.8% and 76.6%, for two IHC surrogate models. The MP/BP NGS kit was successfully validated in a decentralized setting.
Collapse
Affiliation(s)
- Laurence Slembrouck
- KU Leuven - University of Leuven, Department of Oncology, B-3000 Leuven, Belgium.
| | - Lauren Darrigues
- Curie Institute, Department of Surgery, Paris Descartes University, F-75248, France
| | - Cecile Laurent
- Curie Institute, Residual Tumor & Response to Treatment Laboratory, RT2Lab, Paris Descartes University, INSERM, U932 Immunity and Cancer, Paris, F-75248, France
| | - Lorenza Mittempergher
- Agendia, Department of Research and Development, Medical Affairs, Amsterdam, The Netherlands
| | - Leonie Jmj Delahaye
- Agendia, Department of Research and Development, Medical Affairs, Amsterdam, The Netherlands
| | - Isabelle Vanden Bempt
- KU Leuven - University of Leuven, University Hospitals Leuven, Department of Human Genetics, B-3000 Leuven, Belgium
| | - Sara Vander Borght
- KU Leuven - University of Leuven, University Hospitals Leuven, Department of Human Genetics, B-3000 Leuven, Belgium; KU Leuven - University Hospitals Leuven, Department of Pathology, B-3000 Leuven, Belgium
| | - Liesbet Vliegen
- KU Leuven - University of Leuven, University Hospitals Leuven, Department of Human Genetics, B-3000 Leuven, Belgium
| | - Petra Sintubin
- KU Leuven - University of Leuven, University Hospitals Leuven, Department of Human Genetics, B-3000 Leuven, Belgium
| | - Virginie Raynal
- Curie Institute, PSL Research University, Genomics of Excellence (ICGex) Platform, Paris, F-75248, France
| | - Mylene Bohec
- Curie Institute, PSL Research University, Genomics of Excellence (ICGex) Platform, Paris, F-75248, France
| | - Cécile Reyes
- Curie Institute, PSL Research University, Translational Research Department, Genomics Platform, Paris, F-75248, France
| | - Audrey Rapinat
- Curie Institute, PSL Research University, Translational Research Department, Genomics Platform, Paris, F-75248, France
| | - Céline Helsmoortel
- KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, B-3000 Leuven, Belgium
| | - Lynn Jongen
- KU Leuven - University of Leuven, Department of Oncology, B-3000 Leuven, Belgium
| | - Griet Hoste
- KU Leuven - University of Leuven, University Hospitals Leuven, Department of Gynaecology and Obstetrics, B-3000 Leuven, Belgium
| | - Patrick Neven
- KU Leuven - University of Leuven, Department of Oncology, B-3000 Leuven, Belgium; KU Leuven - University of Leuven, University Hospitals Leuven, Department of Gynaecology and Obstetrics, B-3000 Leuven, Belgium
| | - Hans Wildiers
- KU Leuven - University of Leuven, Department of Oncology, B-3000 Leuven, Belgium; KU Leuven - University of Leuven, University Hospitals Leuven, Department of General Medical Oncology, B-3000 Leuven, Belgium
| | - Ann Smeets
- KU Leuven - University of Leuven, Department of Oncology, B-3000 Leuven, Belgium; KU Leuven - University of Leuven, University Hospitals Leuven, Department of Surgical Oncology, B-3000 Leuven, Belgium
| | - Ines Nevelsteen
- KU Leuven - University of Leuven, Department of Oncology, B-3000 Leuven, Belgium; KU Leuven - University of Leuven, University Hospitals Leuven, Department of Surgical Oncology, B-3000 Leuven, Belgium
| | - Kevin Punie
- KU Leuven - University of Leuven, Department of Oncology, B-3000 Leuven, Belgium; KU Leuven - University of Leuven, University Hospitals Leuven, Department of General Medical Oncology, B-3000 Leuven, Belgium
| | - Els Van Nieuwenhuysen
- KU Leuven - University of Leuven, Department of Oncology, B-3000 Leuven, Belgium; KU Leuven - University of Leuven, University Hospitals Leuven, Department of Gynaecology and Obstetrics, B-3000 Leuven, Belgium
| | - Sileny Han
- KU Leuven - University of Leuven, Department of Oncology, B-3000 Leuven, Belgium; KU Leuven - University of Leuven, University Hospitals Leuven, Department of Gynaecology and Obstetrics, B-3000 Leuven, Belgium
| | | | - Enora Laas Faron
- Curie Institute, Department of Surgery, Paris Descartes University, F-75248, France
| | - Timothé Cynober
- Curie Institute, Administration and General Services, Paris, F-75248, France
| | - David Gentien
- Curie Institute, PSL Research University, Translational Research Department, Genomics Platform, Paris, F-75248, France
| | - Sylvain Baulande
- Curie Institute, PSL Research University, Genomics of Excellence (ICGex) Platform, Paris, F-75248, France
| | - Mireille Hj Snel
- Agendia, Department of Research and Development, Medical Affairs, Amsterdam, The Netherlands
| | - Anke T Witteveen
- Agendia, Department of Research and Development, Medical Affairs, Amsterdam, The Netherlands
| | - Sari Neijenhuis
- Agendia, Department of Research and Development, Medical Affairs, Amsterdam, The Netherlands
| | - Annuska M Glas
- Agendia, Department of Research and Development, Medical Affairs, Amsterdam, The Netherlands
| | - Fabien Reyal
- Curie Institute, Department of Surgery, Paris Descartes University, F-75248, France; Curie Institute, Residual Tumor & Response to Treatment Laboratory, RT2Lab, Paris Descartes University, INSERM, U932 Immunity and Cancer, Paris, F-75248, France
| | - Giuseppe Floris
- KU Leuven - University Hospitals Leuven, Department of Pathology, B-3000 Leuven, Belgium; KU Leuven - University of Leuven, Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research
| |
Collapse
|
22
|
Darrigues L, Slembrouck L, Mittempergher L, Delahaye LJ, Vanden Bempt I, Vander Borght S, Vliegen L, Sintubin P, Raynal V, Bohec M, Reyes C, Rapinat A, Helsmoortel C, Jongen L, Hoste G, Neven P, Wildiers H, Smeets A, Nevelsteen I, Punie K, Van Nieuwenhuysen E, Han S, Laurent C, Vincent-Salomon A, Laas-Faron E, Witteveen AT, Neijenhuis S, Glas AM, Floris G, Reyal F. Abstract P4-02-07: Comparison of breast cancer molecular subtyping by Immunohistochemistry and by BluePrint® next generation RNA sequencing-based test at University Hospitals Leuven and Curie Institute Paris. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-02-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
MammaPrint® (MP) and BluePrint® (BP) are microarray-based tests with MP being prognostic for distant recurrence and BP enabling stratification into breast cancer molecular subtypes (Luminal, HER2, Basal-type). Recently, a CE marked MP and BP targeted RNA Next Generation Sequencing (NGS)-based kit was developed at Agendia and validated at University Hospitals Leuven and Curie Institute Paris. Here we compare breast cancer molecular subtype stratification defined by immunohistochemistry (IHC) and by MP and BP NGS- and microarray- based tests.
Patients and Methods
In this study, 124 primary operable invasive breast cancer patients were included at University Hospitals Leuven and at Curie Institute (n=80 Leuven; n=44 Curie) with the following histological subtypes: ductal-NOS (n=100), lobular (n=16), mucinous (n=3), tubular (n=2), others (n=3). Patients with bilateral breast cancer or with >3 positive lymph nodes were excluded. Surrogate breast cancer subtypes based on IHC were defined as follows: luminal if ≥10% estrogen receptor (ER) expression; triple negative if <10% ER and progesterone receptor (PR) expression and HER2 stained negative by IHC and/or FISH; HER2+ if HER2 receptor stained positive (2+ or 3+) by IHC and/or FISH. Luminal subtypes were further stratified into Luminal A-like (HER2 negative, Ki-67<14%, PR≥20%) and Luminal B-like (HER2 negative or positive, Ki-67 ≥14%, PR<20%). When Ki-67% was not available, tumors with grade 1 or 2 were classified as Luminal A-like and with grade 3 as Luminal B-like. IHC subtypes were compared to the BP NGS and microarray molecular subtypes (Luminal-, HER2- and Basal-type). To further stratify BP luminal type tumors, MP test was used as follows: Luminal A (BP Luminal and MP low risk) and Luminal B (BP Luminal and MP high risk).
Results
Concordance between IHC and MP/BP NGS subtyping was 75.0% (93/124), while concordance between MP/BP on NGS and microarray was 89.5% (111/124). MP/BP NGS subtyping identified more low risk Luminal A tumors compared to IHC (54.0%, (67/124) vs 44.3% (55/124)). Notably, concordance was excellent for triple-negative and, to less extent for HER2 driven tumors (Luminal B-like-HER2 positive and HER2+).
IHC vs. MP/BP NGS molecular subtyping (n=124) MP/BP NGSIHCLuminal ALuminal BHER2-positiveBasalTotalLuminal A-like4690055Luminal B-like, HER2-negative16210037Luminal B-like, HER2-positive565016HER2-positive00303Triple negative0101213Total6737812124Microarray vs MP/BP NGS molecular subtyping (n=124) MP/BP NGSMicroarrayLuminal ALuminal BHER2 positiveBasalTotalLuminal A6040064Luminal B7310038HER2-positive028010Basal0001212Total6737812124
Conclusion
This study shows a discordance of 25.0% between IHC and BP/MP NGS subtyping. This is in line with previous findings where IHC was compared to molecular subtyping based on microarray (Viale 2017, Whitworth 2014) underlining the complementarity of genomic testing in early stage breast cancer. Moreover, we observed a high concordance between NGS and microarray molecular subtyping, which suggests a successful translation of the MP/BP microarray test to a MP/BP NGS test.
Citation Format: Darrigues L, Slembrouck L, Mittempergher L, Delahaye LJ, Vanden Bempt I, Vander Borght S, Vliegen L, Sintubin P, Raynal V, Bohec M, Reyes C, Rapinat A, Helsmoortel C, Jongen L, Hoste G, Neven P, Wildiers H, Smeets A, Nevelsteen I, Punie K, Van Nieuwenhuysen E, Han S, Laurent C, Vincent-Salomon A, Laas-Faron E, Witteveen AT, Neijenhuis S, Glas AM, Floris G, Reyal F. Comparison of breast cancer molecular subtyping by Immunohistochemistry and by BluePrint® next generation RNA sequencing-based test at University Hospitals Leuven and Curie Institute Paris [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-02-07.
Collapse
Affiliation(s)
- L Darrigues
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - L Slembrouck
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - L Mittempergher
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - LJ Delahaye
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - I Vanden Bempt
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - S Vander Borght
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - L Vliegen
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - P Sintubin
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - V Raynal
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - M Bohec
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - C Reyes
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - A Rapinat
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - C Helsmoortel
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - L Jongen
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - G Hoste
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - P Neven
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - H Wildiers
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - A Smeets
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - I Nevelsteen
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - K Punie
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - E Van Nieuwenhuysen
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - S Han
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - C Laurent
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - A Vincent-Salomon
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - E Laas-Faron
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - AT Witteveen
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - S Neijenhuis
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - AM Glas
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - G Floris
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - F Reyal
- Curie Institute, Paris, France; KU Leuven - University of Leuven, Leuven, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven – University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Next Generation Sequencing Platform, Genomics Platform, Curie Institute, Paris, France; KU Leuven – University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Curie Institute, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| |
Collapse
|
23
|
Slembrouck L, Laurent C, Delahaye LJ, Mittempergher L, Vanden Bempt I, Vander Borght S, Darrigues L, Vliegen L, Sintubin P, Raynal V, Bohec M, Reyes C, Rapinat A, Helsmoortel C, Jongen L, Hoste G, Neven P, Wildiers H, Smeets A, Nevelsteen I, Punie K, Van Nieuwenhuysen E, Han S, Salomon AV, Faron EL, Cynober T, Witteveen AT, Neijenhuis S, Glas AM, Reyal F, Floris G. Abstract P4-08-25: Decentralized beta testing of MammaPrint and BluePrint NGS kit at University Hospitals Leuven and Curie Institute Paris. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-08-25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Many countries restrict patient material exchange to central diagnostic laboratories abroad, limiting access to assays like MammaPrint® (MP) and BluePrint® (BP). Both assays are microarray-based, with MP being prognostic for distant recurrence and BP for molecular subtyping of breast cancer (Luminal-, HER2-, and Basal-type). To increase accessibility, decentralization is required with Next Generation Sequencing (NGS) being the preferred testing platform given that most diagnostic laboratories have the technology in place. The aim of this beta testing study is to validate a previously developed and centrally validated MP and BP NGS kit for RNA samples in two large tertiary academic hospitals in Europe.
Patients and Methods
Patients with early breast cancer diagnosed at the Multidisciplinary Breast Center at University Hospitals Leuven and Curie Institute Paris were prospectively included between September 2017 and January 2018. Patients with bilateral breast cancer or presenting with more than 3 positive lymph nodes were excluded. Only patients with invasive ductal and invasive lobular carcinoma were included. Twenty tissue sections were cut from formalin-fixed, paraffin-embedded (FFPE) blocks; 10 tissue sections were analyzed at the local site using the MP and BP NGS kit, and 10 tissue sections were analyzed at Agendia using the same kit and procedure, as well as with the golden standard method (gene expression microarrays). Targeted RNA sequencing of the 70 MP and 80 BP signature genes was performed on Illumina MiSeq instruments. The raw NGS data generated at the local test sites was sent through a secure file transfer protocol server to Agendia for interpretation and comparison with microarray and NGS performed in the Agendia laboratories. We aimed for a minimum concordance rate between MP and BP outcome of 90% between each local site and Agendia's centralized site.
Results
In this study, 116 early breast cancer patients were included (73 from University Hospitals Leuven and 43 from Curie Institute). Out of these patients, 52% were MP Low Risk and 48% MP High Risk according to microarray. The patients had a BP luminal, HER2 or basal subtype in respectively 83%, 9% and 8%. Concordance between MP microarray obtained from Agendia and MP NGS obtained from the local sites was 91.4%. Concordance between MP High and Low Risk classification between NGS Leuven versus NGS Agendia was 92.1% and between NGS Curie versus NGS Agendia 95.3%. For BP subtype outcomes, the results from microarray versus NGS for all patients combined from both local sites gave a 98.3% concordance and NGS Agendia versus NGS from each local site gave a 100% concordance.
Conclusion
The MP and BP NGS kit was successfully validated in a decentralized setting, showing high concordance between results obtained at three different sites. There was a clear benefit of having well-trained NGS experienced diagnostic technical teams. The MP and BP NGS kit the first FFPE targeted RNA sequencing based multigene signature for breast cancer care, will provide a high and equal standard of MP and BP gene expression testing for breast cancer in a decentralized setting.
Citation Format: Slembrouck L, Laurent C, Delahaye LJ, Mittempergher L, Vanden Bempt I, Vander Borght S, Darrigues L, Vliegen L, Sintubin P, Raynal V, Bohec M, Reyes C, Rapinat A, Helsmoortel C, Jongen L, Hoste G, Neven P, Wildiers H, Smeets A, Nevelsteen I, Punie K, Van Nieuwenhuysen E, Han S, Salomon AV, Faron EL, Cynober T, Witteveen AT, Neijenhuis S, Glas AM, Reyal F, Floris G. Decentralized beta testing of MammaPrint and BluePrint NGS kit at University Hospitals Leuven and Curie Institute Paris [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-08-25.
Collapse
Affiliation(s)
- L Slembrouck
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - C Laurent
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - LJ Delahaye
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - L Mittempergher
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - I Vanden Bempt
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - S Vander Borght
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - L Darrigues
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - L Vliegen
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - P Sintubin
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - V Raynal
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - M Bohec
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - C Reyes
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - A Rapinat
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - C Helsmoortel
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - L Jongen
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - G Hoste
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - P Neven
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - H Wildiers
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - A Smeets
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - I Nevelsteen
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - K Punie
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - E Van Nieuwenhuysen
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - S Han
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - AV Salomon
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - EL Faron
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - T Cynober
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - AT Witteveen
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - S Neijenhuis
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - AM Glas
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - F Reyal
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| | - G Floris
- KU Leuven - University of Leuven, Leuven, Belgium; Residual Tumor & Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France; Medical Affairs, Agendia, Amsterdam, Netherlands; KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; KU Leuven - University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Next Generation Sequencing Platform, Genomics Platform, Institut Curie, Paris, France; KU Leuven - University of Leuven, University Hospitals Leuven, Genomics Core, Leuven, Belgium; Administration and General Services, Institut Curie, Paris, France; KU Leuven - University of Leuven, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, Department of Pathology, Leuven, Belgium
| |
Collapse
|
24
|
Cuevas M, Carillo C, Reyes C, Stirland A, Rothschild B, Mafi J, Wei E, Sarkisian C. HEALTH INFORMATION SOURCES AMONG OLDER AND YOUNGER PATIENTS AT AN URBAN SAFETY-NET HEALTHCARE CENTER. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.1126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M Cuevas
- UCLA David Geffen School of Medicine, Department of Medicine, Division of Geriatrics
| | - C Carillo
- Medicine-Division of Geriatrics, UCLA
| | - C Reyes
- UCLA David Geffen School of Medicine, Department of Medicine, Division of Geriatrics
| | - A Stirland
- Los Angeeles County Department of Public Health
| | | | - J Mafi
- UCLA David Geffen School of Medicine, Department of Medicine, Division of General Internal Medicine
| | | | - C Sarkisian
- UCLA David Geffen School of Medicine, Department of Medicine, Division of Geriatrics
| |
Collapse
|
25
|
Montenegro S, Contreras SP, Reyes C, de la Barra T, Quiroz A, Herrera J, Elgorriaga E, Mucientes F. Prognostic value of HPV status and tumoral markers (p16/Ki67) in chilean patients with anal cancer. Int J Infect Dis 2018. [DOI: 10.1016/j.ijid.2018.04.3811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
26
|
Coussy F, Bernard V, Lavigne M, Boulai A, Chateau-Joubert S, Dahmani A, Montaudon E, Reyes C, Botty RE, Pieron G, Laurent C, Melaabi S, Salomon AV, Bièche I, Marangoni E. Abstract 2973: A comprehensive panel of patient-derived xenografts representing the molecular heterogeneity and diversity of triple-negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-2973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous disease. Patients diagnosed with TNBC have a poor prognosis and identification of new biomarkers and therapeutic agents is a high priority. Patient-derived xenografts (PDX) are clinically relevant models that have emerged as important tool for the analysis of drug activity and predictive biomarker discovery. The purpose of this work was to analyze the molecular heterogeneity of a large panel of TNBC PDX with the perspective to test targeted therapy and to identify biomarkers of response.
Experimental Design: PDX of early-stage TNBC established from 2003 to 2016 (N=60) were analyzed by high-resolution array CGH and gene expression profiling (Cytoscan HD and Human Gene 1.1 ST arrays). Subtypes were identified with the tool TNBCtype (Chen et al., 2012) based on transcriptomic data. A targeted next-generation sequencing (NGS) of 100 genes (the top frequently mutated genes in breast cancer) was performed on Illumina HiSeq2500 sequencer. COSMIC, Tumorportal and cBioportal databases were used for the interpretation of genomic variants. Immunohistochemistry (IHC) and morphologic analysis of PDX were performed as compared to the corresponding patients' tumors. PDX carrying targetable genomic alterations in the PI3K/AKT/mTOR and MAPK signaling pathways were treated by specific inhibitors (selumetinib, BAY 80-6946 and PF-04691502).
Results: At the gene expression level, TNBC PDX represent all the different TNBC subtypes identified by the Lehmann classification. The frequency of the different TNBC subtypes was similar to the TGCA TNBC, except for the immunomodulatory subtype, underrepresented in PDX. Somatic pathologic mutations and copy number alterations were similar in PDX and TCGA TNBC patients. Among the top altered genes are TP53 and oncogenes and tumor suppressors of the PI3K/AKT/mTOR and MAPK pathways (including PIK3CA, AKT1, NF1 and NRAS/KRAS). At the histologic level, TNBC PDX were mainly composed of invasive ductal carcinoma of no special type, with some tumors being classified as apocrine or metaplastic carcinomas. Comparison with the original tumors show similar patterns (based on IHC analysis of CK5, CK8/18, CK14 and AR, FOXA1, EGFR and Ki67). In vivo efficacy experiments with PI3K and MAPK pathways inhibitors showed marked antitumor activity in PDX carrying genomic alterations of PIK3CA, AKT1 and NRAS, NF1 genes. Drug combination experiments are currently ongoing in PDX with simultaneous genomic alterations of PI3KCA and MAPK related genes.
Conclusions: TNBC PDX reproduce the molecular heterogeneity and diversity of TNBC patients. This large collection of PDX is a clinically relevant platform for drug testing, biomarker discovery and translational research.
Citation Format: Florence Coussy, Virginie Bernard, Marion Lavigne, Anais Boulai, Sophie Chateau-Joubert, Ahmed Dahmani, Elodie Montaudon, Cécile Reyes, Rania El Botty, Gaëlle Pieron, Cécile Laurent, Samia Melaabi, Anne Vincent Salomon, Ivan Bièche, Elisabetta Marangoni. A comprehensive panel of patient-derived xenografts representing the molecular heterogeneity and diversity of triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2973.
Collapse
|
27
|
Tlemsani C, Pasmant E, Boudou-Rouquette P, Bellesoeur A, Even J, Larousserie F, Reyes C, Gentien D, Alexandre J, Vidaud M, Anract P, Leroy K, Goldwasser F. BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine. Am J Med Sci 2018; 356:404-407. [PMID: 30041945 DOI: 10.1016/j.amjms.2018.04.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2018] [Revised: 04/24/2018] [Accepted: 04/28/2018] [Indexed: 02/01/2023]
Abstract
We report the case of a patient with a BRCA2 germline mutation who developed a localized pleomorphic soft tissue sarcoma of the leg with poor prognostic features. BRCA2 germline mutations were not previously reported to be associated with pleomorphic sarcoma. BRCA2 loss-of-heterozygosity was found in the tumor, resulting in a complete BRCA2 loss-of-function. BRCA2 deficiency is associated with sensitivity to cisplatin-based chemotherapy in breast and ovarian cancer patients. We used a cisplatin-based chemotherapy. A rapid major partial response was obtained, which allowed a curative and conservative surgical resection of the sarcoma followed by adjuvant irradiation. This case illustrates that sarcoma patients may present unexpected but targetable genetic abnormalities and that BRCA2 loss-of-function may be targetable in sarcoma as it is associated with enhanced sensitivity to cisplatin. Our observation emphasizes the input of genomic medicine in clinical practice, its importance for treatment decisions, and the overlap between constitutional and somatic genetics.
Collapse
Affiliation(s)
- Camille Tlemsani
- Molecular Genetic and Biology Department, Netsarc National Network, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, Paris, France; EA7331 Department, Université Paris Descartes, Paris, France; Medical Oncology Department, Netsarc National Network, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, Paris,France.
| | - Eric Pasmant
- Molecular Genetic and Biology Department, Netsarc National Network, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, Paris, France; EA7331 Department, Université Paris Descartes, Paris, France
| | - Pascaline Boudou-Rouquette
- Medical Oncology Department, Netsarc National Network, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, Paris,France
| | - Audrey Bellesoeur
- Medical Oncology Department, Netsarc National Network, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, Paris,France
| | - Julien Even
- Orthopedic Surgery Department, Netsarc National Network, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, Paris, France
| | - Frédérique Larousserie
- Pathology Department, Sarcoma Center, Netsarc National Network, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, Paris, France
| | - Cécile Reyes
- Translational Research Department, Institut Curie, PSL Research University, Genomics Platform, Paris, France
| | - David Gentien
- Translational Research Department, Institut Curie, PSL Research University, Genomics Platform, Paris, France
| | - Jérôme Alexandre
- Medical Oncology Department, Netsarc National Network, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, Paris,France
| | - Michel Vidaud
- Molecular Genetic and Biology Department, Netsarc National Network, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, Paris, France; EA7331 Department, Université Paris Descartes, Paris, France
| | - Philippe Anract
- Orthopedic Surgery Department, Netsarc National Network, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, Paris, France
| | - Karen Leroy
- Molecular Genetic and Biology Department, Netsarc National Network, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, Paris, France
| | - François Goldwasser
- Medical Oncology Department, Netsarc National Network, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, Paris,France
| |
Collapse
|
28
|
Satram-Hoang S, Bajaj PS, Stein A, Hoang KQ, Momin F, Cortazar P, Reyes C. Abstract P6-13-02: Increased mortality risk among elderly patients with early stage triple negative breast cancer who did not receive adjuvant or neoadjuvant therapy. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-13-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Worldwide, breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer death in women. The triple negative (TN) subtype accounts for up to 20% of BC and has a poorer prognosis compared to other subtypes. We set out to evaluate treatment patterns and survival associated with receiving adjuvant or neo-adjuvant therapy in an older, demographically diverse population of patients with TNBC.
Methods: The analysis included 10,694 patients with first primary TNBC from the linked SEER-Medicare database. Patients were diagnosed with Stage I-III disease between January 1, 2001-December 31, 2011, ≥66 years, continuously enrolled in Medicare Parts A and B in the year prior to diagnosis, and underwent breast cancer surgery within 6 months after diagnosis. Unadjusted Kaplan Meier analyses and time-varying Cox proportional hazards regression adjusting for patient characteristics assessed overall survival. Date of last follow-up was December 31, 2013.
Results: There were 4,807 (45%) patients treated with adjuvant/neo-adjuvant chemotherapy and 5,887 (55%) untreated. Treatment rates increased over the study time-period from 45% in 2001 to 52% in 2011 (p<.0001). Compared to treated patients, untreated patients were older (78 vs. 73 years), had earlier stage disease (57% vs. 31% Stage I), lower tumor grade (34% vs. 23% grade 1/2), smaller tumors (57 vs.40% <2cm), poorer performance (13% vs. 6%), higher comorbidity burden (45% vs. 37% NCI Comorbidity Score ≥ 1) and were less likely to receive radiotherapy (47% vs. 65%; p<0.0001). The median unadjusted overall survival was 94.3 months for the overall population and was longer for treated patients (101.5 months) compared to untreated patients (88.4 months; log rank p <.0001). In the adjusted Cox model, there was a 28% higher risk of death in untreated compared to treated patients (HR=1.28; 95% CI=1.19-1.38). The model also showed that as age, stage, tumor size, tumor grade, and comorbidity score increased, mortality risk also significantly increased. Having poor performance indicators was also significantly associated with higher mortality risks, while prior radiotherapy was associated with lower risks.
Conclusions: Although therapy use has increased over time, this large observational study confirmed that 55% of elderly patients with Stage I-III TNBC are not receiving adjuvant/neo-adjuvant therapy following diagnosis. As a result, untreated patients exhibited a significantly elevated risk of death compared to those who received treatment. The results of this study highlight the unmet need in this patient population and provide an important context to optimize disease management in real-world settings.
Citation Format: Satram-Hoang S, Bajaj PS, Stein A, Hoang KQ, Momin F, Cortazar P, Reyes C. Increased mortality risk among elderly patients with early stage triple negative breast cancer who did not receive adjuvant or neoadjuvant therapy [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-13-02.
Collapse
Affiliation(s)
- S Satram-Hoang
- Q.D. Research, Granite Bay, CA; Genentech, Inc., South San Francisco, CA
| | - PS Bajaj
- Q.D. Research, Granite Bay, CA; Genentech, Inc., South San Francisco, CA
| | - A Stein
- Q.D. Research, Granite Bay, CA; Genentech, Inc., South San Francisco, CA
| | - KQ Hoang
- Q.D. Research, Granite Bay, CA; Genentech, Inc., South San Francisco, CA
| | - F Momin
- Q.D. Research, Granite Bay, CA; Genentech, Inc., South San Francisco, CA
| | - P Cortazar
- Q.D. Research, Granite Bay, CA; Genentech, Inc., South San Francisco, CA
| | - C Reyes
- Q.D. Research, Granite Bay, CA; Genentech, Inc., South San Francisco, CA
| |
Collapse
|
29
|
Martínez-Laguna D, Reyes C, Carbonell-Abella C, Losada Grande E, Soldevila Madorell B, Mauricio D, Díez-Pérez A, Nogués X, Prieto-Alhambra D. Uso de fármacos para la osteoporosis en pacientes con diabetes mellitus tipo 2: estudio de cohortes de base poblacional. Rev Osteoporos Metab Miner 2017. [DOI: 10.4321/s1889-836x2017000400002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023] Open
|
30
|
Reyes C, Tebe C, Martinez-Laguna D, Ali MS, Soria-Castro A, Carbonell C, Prieto-Alhambra D. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos Int 2017; 28:2997-3004. [PMID: 28714038 DOI: 10.1007/s00198-017-4144-7] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Accepted: 07/04/2017] [Indexed: 12/30/2022]
Abstract
UNLABELLED Adherence to anti-osteoporosis medications is poor. We carried out a cohort study using a real-world population database to estimate the persistence of anti-osteoporosis drugs. Unadjusted 2-year persistence ranged from 10.3 to 45.4%. Denosumab users had a 40% lower risk of discontinuation at 2 years compared to alendronate users. PURPOSE The purpose of this study was to estimate real-world persistence amongst incident users of anti-osteoporosis medications. METHODS This is a retrospective cohort using data from anonymised records and dispensation data ( www.sidiap.org ). Eligibility comprised the following: women aged ≥50, incident users of anti-osteoporosis medication (2012), with data available for at least 12 months prior to therapy initiation. Exclusions are other bone diseases/treatments and uncommon anti-osteoporosis drugs (N < 100). Follow-up was from first pharmacy dispensation until cessation, end of study, censoring or switching. Outcomes are 2- and 1-year persistence with a permissible gap of up to 90 days. Persistence with alendronate was compared to other bisphosphonates, strontium ranelate, selective oestrogen receptor modulators, teriparatide and denosumab. Cox models were used to estimate hazard ratios of therapy cessation according to drug used after adjustment for age, sex, BMI, smoking, alcohol drinking, Charlson co-morbidity index, previous fractures, use of anti-osteoporosis medication/s, oral corticosteroids and socio-economic status. RESULTS A total of 19,253 women were included. Unadjusted 2-year persistence [95% CI] ranged from 10.3% [9.1-11.6%] (strontium ranelate) to 45.4% [43.1-47.8%] (denosumab). One-year persistence went from 35.8% [33.9%-37.7%] (strontium ranelate) to 65.8% [63.6%-68.0%] (denosumab). At the end of the first year and compared to alendronate users, both teriparatide and denosumab users had reduced cessation risk (adjusted HR 0.76, 95% CI 0.67-0.86 and 0.54, 95% CI 0.50-0.59 respectively) while at the end of the second year, only denosumab had a lower risk of discontinuation (adjusted HR 0.60, 95% CI 0.56-0.64). CONCLUSIONS Unadjusted 2-year persistence is suboptimal. However, both teriparatide and denosumab users had better 1-year persistence and only denosumab had 2-year better persistence compared to alendronate users. Unmeasured confounding by indication might partially explain our findings.
Collapse
Affiliation(s)
- C Reyes
- GREMPAL (Grup de Recerca en Epidemiologia de les Malalties Prevalents de l'Aparell Locomotor) Research Group, IDIAP Jordi Gol (Universitat Autònoma de Barcelona), CIBER Fes, Av Gran Via de les Corts Catalanes, 587, Atic, 08007, Barcelona, Spain
| | - C Tebe
- Bellvitge Biomedical Research Institute (IDIBELL), Avinguda Granvia, 199-203, 08908, L'Hospitalet de Llobregat, Spain
- Faculty of Medicine and Health Sciences, Rovira i Virgili University, Reus, Spain
| | - D Martinez-Laguna
- GREMPAL (Grup de Recerca en Epidemiologia de les Malalties Prevalents de l'Aparell Locomotor) Research Group, IDIAP Jordi Gol (Universitat Autònoma de Barcelona), CIBER Fes, Av Gran Via de les Corts Catalanes, 587, Atic, 08007, Barcelona, Spain
- Atenció Primària Barcelona, Institut Català de la Salut (ICS), Balmes 22, 08007, Barcelona, Spain
| | - M S Ali
- Musculoskeletal Pharmaco and Device Epidemiology, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK
| | - A Soria-Castro
- GREMPAL (Grup de Recerca en Epidemiologia de les Malalties Prevalents de l'Aparell Locomotor) Research Group, IDIAP Jordi Gol (Universitat Autònoma de Barcelona), CIBER Fes, Av Gran Via de les Corts Catalanes, 587, Atic, 08007, Barcelona, Spain
- Atenció Primària Barcelona, Institut Català de la Salut (ICS), Balmes 22, 08007, Barcelona, Spain
| | - C Carbonell
- GREMPAL (Grup de Recerca en Epidemiologia de les Malalties Prevalents de l'Aparell Locomotor) Research Group, IDIAP Jordi Gol (Universitat Autònoma de Barcelona), CIBER Fes, Av Gran Via de les Corts Catalanes, 587, Atic, 08007, Barcelona, Spain
- Atenció Primària Barcelona, Institut Català de la Salut (ICS), Balmes 22, 08007, Barcelona, Spain
| | - D Prieto-Alhambra
- GREMPAL (Grup de Recerca en Epidemiologia de les Malalties Prevalents de l'Aparell Locomotor) Research Group, IDIAP Jordi Gol (Universitat Autònoma de Barcelona), CIBER Fes, Av Gran Via de les Corts Catalanes, 587, Atic, 08007, Barcelona, Spain.
- Musculoskeletal Pharmaco and Device Epidemiology, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK.
- Musculoskeletal Research Unit, IMIM-Parc Salut Mar, Universitat Autònoma de Barcelona, Doctor Aiguader 88, 08003, Barcelona, Spain.
| |
Collapse
|
31
|
Satram-Hoang S, Bajaj P, Stein A, Hoang K, Momin F, Cortazar P, Reyes C. Real-world treatment patterns and outcomes among elderly metastatic triple negative breast cancer patients in the United States. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
Martinez-Laguna D, Nogues X, Abrahamsen B, Reyes C, Carbonell-Abella C, Diez-Perez A, Prieto-Alhambra D. Excess of all-cause mortality after a fracture in type 2 diabetic patients: a population-based cohort study. Osteoporos Int 2017; 28:2573-2581. [PMID: 28744600 DOI: 10.1007/s00198-017-4096-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Accepted: 05/15/2017] [Indexed: 01/09/2023]
Abstract
UNLABELLED Post-fracture mortality in type 2 diabetes mellitus (T2DM) patients has been poorly studied. We report an absolute and relative excess all-cause mortality following a fracture in these patients compared to non-diabetic patients. INTRODUCTION T2DM and osteoporotic fractures are independently associated with a reduced lifespan, but it is unknown if T2DM confers an excess post-fracture mortality compared to non-diabetic fracture patients. We report post-fracture all-cause mortality according to T2DM status. METHODS This is a population-based cohort study using data from the SIDIAP database. All ≥50 years old T2DM patients registered in SIDIAP in 2006-2013 and two diabetes-free controls matched on age, gender, and primary care center were selected. Study outcome was all-cause mortality following incident fractures. Participants were followed from date of any fracture (AF), hip fracture (HF), and clinical vertebral fracture (VF) until the earliest of death or censoring. Cox regression was used to calculate mortality according to T2DM status after adjustment for age, gender, body mass index, smoking, alcohol intake, and previous ischemic heart and cerebrovascular disease. RESULTS We identified 166,106 T2DM patients and 332,212 non-diabetic, of which 11,066 and 21,564, respectively, sustained a fracture and were then included. Post-fracture mortality rates (1000 person-years) were (in T2DM vs non-diabetics) 62.7 vs 49.5 after AF, 130.7 vs 112.7 after HF, and 54.9 vs 46.2 after VF. Adjusted HR (95% CI) for post-AF, post-HF, and post-VF mortality was 1.30 (1.23-1.37), 1.28 (1.20-1.38), and 1.20 (1.06-1.35), respectively, for T2DM compared to non-diabetics. CONCLUSIONS T2DM patients have a 30% increased post-fracture mortality compared to non-diabetics and a remarkable excess in absolute mortality risk. More research is needed on the causes underlying such excess risk, and on the effectiveness of measures to reduce post-fracture morbi-mortality in T2DM subjects.
Collapse
Affiliation(s)
- D Martinez-Laguna
- GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute, CIBERFES ISCIII, Universitat Autonoma de Barcelona, Barcelona, Spain
- Ambit Barcelona, Primary Care Department, Institut Catala de la Salut, Barcelona, Spain
| | - X Nogues
- Internal Medicine Department IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - B Abrahamsen
- Department of Medicine, Holbæk Hospital, Holbæk, Denmark
- OPEN Odense Patient Data Explorative Network, Institute of Clinical Research, Department of Clinical Research, University of Southern Denmark, Odense, Denmark
| | - C Reyes
- GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute, CIBERFES ISCIII, Universitat Autonoma de Barcelona, Barcelona, Spain
| | - C Carbonell-Abella
- GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute, CIBERFES ISCIII, Universitat Autonoma de Barcelona, Barcelona, Spain
- Ambit Barcelona, Primary Care Department, Institut Catala de la Salut, Barcelona, Spain
| | - A Diez-Perez
- Internal Medicine Department IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Autonomous University of Barcelona and CIBERFES, ISCIII, Barcelona, Catalonia, Spain
| | - D Prieto-Alhambra
- GREMPAL Research Group, Idiap Jordi Gol Primary Care Research Institute, CIBERFES ISCIII, Universitat Autonoma de Barcelona, Barcelona, Spain.
- Internal Medicine Department IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
- Autonomous University of Barcelona and CIBERFES, ISCIII, Barcelona, Catalonia, Spain.
- MRC Lifecourse Epidemiology Unit, Southampton University, Southampton, UK.
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford NIHR Musculoskeletal Biomedical Research Centre, University of Oxford, Oxford, UK.
- Musculoskeletal Pharmaco and Device Epidemiology, Botnar Research Centre, Nuffield Orthopaedics Centre, Windmill Road, Oxford, OX3 7LD, UK.
| |
Collapse
|
33
|
Roth J, Bajaj P, Sullivan S, Reyes C, Antao V, Stein A, Mahtani R, Ramsey S. Survival gains from advances in first-line systemic therapy for HER2-positive metastatic breast cancer in the U.S., 1995-2015. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.026] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Bajaj P, Latremouille-Viau D, Guerin A, Reyes C, Stein A, Kurian A, Cortazar P. What are the treatment patterns and overall survival (OS) in patients with metastatic triple-negative breast cancer (mTNBC) in US clinical practice? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.031] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Menkin J, Araiza D, Reyes C, Trejo L, Choi S, Willis P, McCreath H, Sarkisian C. ETHNICITY DIFFERENCES IN EXPECTATIONS REGARDING AGING AMONG MINORITY SENIORS. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.2253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- J. Menkin
- University of California, Los Angeles, LosAngeles, California,
| | - D. Araiza
- University of California, Los Angeles, LosAngeles, California,
| | - C. Reyes
- University of California, Los Angeles, LosAngeles, California,
| | - L. Trejo
- City of Los Angeles, Los Angeles, California,
| | - S. Choi
- University of California, Los Angeles, LosAngeles, California,
| | - P. Willis
- Watts Labor Community Action Committee, Los Angeles, California
| | - H. McCreath
- University of California, Los Angeles, LosAngeles, California,
| | - C.A. Sarkisian
- University of California, Los Angeles, LosAngeles, California,
| |
Collapse
|
36
|
Sarkisian C, Song S, Reyes C, Carrillo C, Jimenez E, Ma S, Trejo L. WORTH THE WALK: A CULTURALLY-TAILORED INTERVENTION TO REDUCE STROKE RISK IN MINORITY OLDER ADULTS. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.3269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - S. Song
- Rush University, Chicago, Illinois,
| | - C. Reyes
- UCLA School of Medicine, Los Angeles, California,
| | | | - E. Jimenez
- Mexican American Opportunity Foundation, Los Angeles, California,
| | - S. Ma
- Chinatown Service Center, Los Angeles, California,
| | - L. Trejo
- City of Los Angeles Department of Aging, Los Angeles, California
| |
Collapse
|
37
|
Chu L, Yoo B, Carrigan G, Lai C, Beattie M, Reyes C. Abstract P5-08-24: How do real-world treatment patterns compare to guideline recommendations for first-line metastatic breast cancer patients in US community clinics? Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-08-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Treatment (txt) guidelines are based on trial data from a small minority of patients (pts). Linked electronic health records (EHRs) are a novel approach to examine txt patterns and outcomes in larger and more generalizable populations. Given the increasing importance of real world data and real world outcomes, we utilized linked EHRs from a network of US community clinics to examine how real world txt patterns compare to metastatic breast cancer (mBC) txt guideline recommendations.
Methods:
The Flatiron database provides real world clinical data collected from EHRs used by US cancer care providers. The Flatiron network comprises ~15% of US cancer pts and is geographically and demographically diverse.
Using EHR from Jan 2016 mBC database, we evaluated first-line (1L) txt patterns in mBC by molecular subtype. Pts were selected if they received mBC txt within 60 days of mBC diagnosis between 01Jan2011-31Dec2015, had ≥2 visits within the Flatiron Network on or after 01Jan2013, and were ≥18 years (yrs). Analyses were conducted to describe pt and clinical characteristics and 1L txt by HER2 and/or hormone receptor (HR) status.
Results:
Among 2509 mBC pts identified, 58.9% were HR+/HER2-, 17.7% HER2+, 11.6% HR-/HER2- (triple negative, TNBC), 7.4% HER2 equivocal, and 4.3% 'not done/unknown HER2 status'. Txt patterns in the latter two groups were not analyzed. Selected pt and disease characteristics by subtype are shown in Table 1. Median follow-up since mBC diagnosis was 1.1 yrs (range 0-5 yrs). The 1L mBC txts by subtype are shown in Table 2. Pts with HR+/HER2- subtype were treated primarily with hormonal therapy (68%) and/or chemotherapy (chemo) (35%). Among HER2+ pts, the 1L mBC txt patterns include trastuzumab+pertuzumab with chemo (31%), trastuzumab with chemo (22%), trastuzumab with hormonal therapy (9%), ado-trastuzumab (4%), lapatinib with chemo (3%), and lapatinib with hormonal therapy (1%). For TNBC, the majority received chemo (95%), such as paclitaxel (21%), nab-paclitaxel (13%) and docetaxel (12%).
Conclusion:
This study advances our current understanding of real world 1L patterns of care by molecular subtype among mBC pts and how these compare to guideline recommendations. While the majority of pts are receiving therapy per guidelines, up to 22% of HER2+ of pts are not receiving targeted therapy in 1L mBC
Table 1. Patient and disease characteristics by subtypeN (%)HR+/HER2- (N=1479)HER2+ (N=445)TNBC (N=291)Age at mBC diagnosis (yrs), median (range)66 (24-85)60 (27-85)60 (33-85)Sex Female1459 (99)441 (99)289 (99)Race White995 (67)274 (62)168 (58)Black112 (8)44 (10)42 (14)Asian19 (1)14 (3)5 (2)Other179 (12)50 (11)36 (12)Missing173 (12)63 (14)40 (14)MBC type De novo418 (28)172 (39)94 (32)Recurrent881 (60)225 (51)178 (61)Unknown180 (12)48 (11)19 (7)HR Status Positive1479 (100)300 (67)--Negative--145 (33)291 (100)
Table 2. 1L mBC treatments by subtypeN (%)HR+/HER2- (N=1479)HER2+ (N=445)TNBC (N=291)Any Targeted Therapy*77 (5)346 (78)12 (4)Any Chemotherapy521 (35)283 (64)276 (95)Any Hormonal Therapy1010 (68)115 (26)16 (6)*Targeted therapy includes trastuzumab, pertuzumab, ado-trastuzumab emtansine, lapatinib and bevacizumab
Citation Format: Chu L, Yoo B, Carrigan G, Lai C, Beattie M, Reyes C. How do real-world treatment patterns compare to guideline recommendations for first-line metastatic breast cancer patients in US community clinics? [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-24.
Collapse
Affiliation(s)
- L Chu
- Genentech, Inc, South San Francisco, CA
| | - B Yoo
- Genentech, Inc, South San Francisco, CA
| | | | - C Lai
- Genentech, Inc, South San Francisco, CA
| | - M Beattie
- Genentech, Inc, South San Francisco, CA
| | - C Reyes
- Genentech, Inc, South San Francisco, CA
| |
Collapse
|
38
|
Lemaître S, Lecler A, Lévy-Gabriel C, Reyes C, Desjardins L, Gentien D, Zmuda M, Jacomet PV, Lumbroso-Le Rouic L, Dendale R, Vincent-Salomon A, Pierron G, Galatoire O, Cassoux N. Evisceration and ocular tumors: What are the consequences? J Fr Ophtalmol 2017; 40:93-101. [PMID: 28126270 DOI: 10.1016/j.jfo.2016.10.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2016] [Revised: 10/04/2016] [Accepted: 10/05/2016] [Indexed: 10/20/2022]
Abstract
PURPOSE Evisceration can be performed for blind, painful eyes. This surgery can promote the dissemination of tumor cells within the orbit if an ocular tumor has been missed preoperatively. METHODS We reviewed the medical records of patients who were eviscerated for blind, painful eyes between 2009 and 2014 and who were referred after the surgery to the Institut Curie or the Rothschild Foundation in Paris. We included the patients with a histological diagnosis of ocular tumor or orbital recurrence. Cytogenetic analysis was performed whenever possible. RESULTS Four patients turned out to have an ocular tumor after evisceration (two choroidal melanomas, a rhabdoid tumor and an adenocarcinoma of the retinal pigment epithelium); two had a history of prior ocular trauma. The tumors were diagnosed either on histological analysis of the intraocular contents (2 patients) or biopsy of orbital recurrence (2 patients). Prior to evisceration, fundus examination was not performed in 3 patients. One had preoperative imaging but no intraocular tumor was suspected. At the time of this study, 3 patients had had an orbital recurrence and died. We also found 2 patients who had an evisceration despite a past history of choroidal melanoma treated with proton beam therapy. CONCLUSION We showed that evisceration of eyes with unsuspected ocular malignancies was associated with a poor prognosis due to orbital recurrence and metastasis. The evisceration specimen should therefore always be sent for histological analysis in order to perform prompt adjuvant orbital radiotherapy if an ocular tumor is found.
Collapse
Affiliation(s)
- S Lemaître
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France; Université Paris Descartes, 12, rue de l'École-de-Médecine, 75270 Paris cedex 06, France.
| | - A Lecler
- Fondation ophtalmologique Adolphe de Rothschild, 25-29, rue Manin, 75019 Paris, France
| | | | - C Reyes
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - L Desjardins
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - D Gentien
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - M Zmuda
- Fondation ophtalmologique Adolphe de Rothschild, 25-29, rue Manin, 75019 Paris, France
| | - P V Jacomet
- Fondation ophtalmologique Adolphe de Rothschild, 25-29, rue Manin, 75019 Paris, France
| | | | - R Dendale
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France; ICPO centre de protonthérapie, 15, rue Georges-Clemenceau, 91400 Orsay, France
| | | | - G Pierron
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - O Galatoire
- Fondation ophtalmologique Adolphe de Rothschild, 25-29, rue Manin, 75019 Paris, France
| | - N Cassoux
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France
| |
Collapse
|
39
|
Ortiz S, Ceballos MJ, González CR, Reyes C, Gómez V, García A, Solari A. Trypanosoma cruzi diversity in infected dogs from areas of the north coast of Chile. Vet Parasitol Reg Stud Reports 2016; 5:42-47. [PMID: 31014537 DOI: 10.1016/j.vprsr.2016.09.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Revised: 09/13/2016] [Accepted: 09/19/2016] [Indexed: 01/10/2023]
Abstract
As part of a multi-site research program on the eco-epidemiology and control of Chagas disease in northern Chile, we sought to identify the Trypanosoma cruzi discrete typing units (DTUs) infecting rural and peridomestic dogs, using direct methods without grown of the parasite in the laboratory and thus to assess the use of this species as a sentinel of the disease in well-defined endemic areas of T. cruzi in Chile. Infected dogs (35) from three villages were included in the study. The studied villages were Caleta Río Seco and Caleta San Marcos, both in the Tarapacá Region, and La Serena in the Coquimbo Region. These villages were selected based on previous evidence of Mepraia infection reports of the Chilean Ministry of Health. Amplicons from nested-PCR positive samples were used as targets to determine the infective T. cruzi DTUs circulating in blood using PCR-DNA blotting and hybridization assays with five specific DNA probes (TcI, TcII, TcIII, TcV and TcVI). Results of hybridization with dog samples from Caleta Rio Seco showed single infections in 2 out of 16 and mixed infections in 14 out of 16. TcVI was the most frequent DTU found in this area. A highlight is that for the first time the presence of TcIII is reported in this area. Samples from Caleta San Marcos showed single infections in 5 out of 9 and mixed infections in 4 out of 9. TcVI was the most frequent DTU found in this area. Samples from La Serena showed single infections in 5 out of 10 and mixed infections in 2 out of 10; we were unable to genotype the other 3 samples. Our results indicate that infection by T. cruzi DTUs in dogs is not homogeneously distributed but rather specific to each region of our country, as demonstrated by the differences in the T. cruzi DTU distribution in some localities.
Collapse
Affiliation(s)
- S Ortiz
- Programa de Biología Celular y Molecular, ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Chile
| | - M J Ceballos
- Escuela de Medicina Veterinaria, Facultad de Ciencias Agropecuarias, Universidad Pedro de Valdivia, La Serena, Chile
| | - C R González
- Instituto de Entomología, Facultad de Ciencias Básicas, Universidad, Metropolitana de Ciencias de la Educación, Santiago, Chile; Laboratorio de Entomología Médica, Sección Parasitología, Instituto de Salud, Pública de, Chile
| | - C Reyes
- Laboratorio de Entomología Médica, Sección Parasitología, Instituto de Salud, Pública de, Chile
| | - V Gómez
- Facultad de Medicina, Universidad Pedro de Valdivia, La Serena, Chile
| | - A García
- Facultad de Medicina, Universidad Pedro de Valdivia, La Serena, Chile
| | - A Solari
- Programa de Biología Celular y Molecular, ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
| |
Collapse
|
40
|
Chicard M, Boyault S, Colmet Daage L, Richer W, Gentien D, Pierron G, Lapouble E, Bellini A, Clement N, Iacono I, Bréjon S, Carrere M, Reyes C, Hocking T, Bernard V, Peuchmaur M, Corradini N, Faure-Conter C, Coze C, Plantaz D, Defachelles AS, Thebaud E, Gambart M, Millot F, Valteau-Couanet D, Michon J, Puisieux A, Delattre O, Combaret V, Schleiermacher G. Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma. Clin Cancer Res 2016; 22:5564-5573. [DOI: 10.1158/1078-0432.ccr-16-0500] [Citation(s) in RCA: 77] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2016] [Revised: 06/04/2016] [Accepted: 06/28/2016] [Indexed: 11/16/2022]
|
41
|
González A, Bonilla J, Quintero M, Reyes C, Chavarro A. Análisis de las causas y consecuencias de los accidentes laborales ocurridos en dos proyectos de construcción. ACTA ACUST UNITED AC 2016. [DOI: 10.4067/s0718-50732016000100001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
42
|
Piqueret-Stephan L, Marcaillou C, Reyes C, Honoré A, Letexier M, Gentien D, Droin N, Lacroix L, Scoazec JY, Vielh P. Massively parallel DNA sequencing from routinely processed cytological smears. Cancer Cytopathol 2015; 124:241-53. [DOI: 10.1002/cncy.21639] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2015] [Revised: 10/03/2015] [Accepted: 10/05/2015] [Indexed: 11/07/2022]
Affiliation(s)
| | | | - Cécile Reyes
- Genomic Platform, Translational Research Department; Institut Curie; Paris France
| | - Aurélie Honoré
- Analyse Moléculaire, Modélisation et Imagerie de la maladie Cancéreuse (AMMICa) CNRS Unité Mixte de Service 3655, INSERM US23, Paris Sud University), Translational Research Laboratory; Gustave Roussy Villejuif France
| | | | - David Gentien
- Genomic Platform, Translational Research Department; Institut Curie; Paris France
| | - Nathalie Droin
- Gustave Roussy; Villejuif France
- Unit 1009, INSERM; Villejuif France
| | - Ludovic Lacroix
- Analyse Moléculaire, Modélisation et Imagerie de la maladie Cancéreuse (AMMICa) CNRS Unité Mixte de Service 3655, INSERM US23, Paris Sud University), Translational Research Laboratory; Gustave Roussy Villejuif France
- Department of Biopathology; Gustave Roussy Villejuif France
| | - Jean-Yves Scoazec
- Analyse Moléculaire, Modélisation et Imagerie de la maladie Cancéreuse (AMMICa) CNRS Unité Mixte de Service 3655, INSERM US23, Paris Sud University), Translational Research Laboratory; Gustave Roussy Villejuif France
- Department of Biopathology; Gustave Roussy Villejuif France
| | - Philippe Vielh
- Gustave Roussy; Villejuif France
- Unité Mixte de Recherche 981, INSERM; Villejuif France
- Analyse Moléculaire, Modélisation et Imagerie de la maladie Cancéreuse (AMMICa) CNRS Unité Mixte de Service 3655, INSERM US23, Paris Sud University), Translational Research Laboratory; Gustave Roussy Villejuif France
- Department of Biopathology; Gustave Roussy Villejuif France
| |
Collapse
|
43
|
Donkervoort S, Chan S, Bradley N, Foley A, Nguyen D, Hu Y, Leach M, Thangarajh M, Reyes C, Nance J, Moore S, Bönnemann C. Cytoplasmic body pathology in severe ACTA1-myopathy in the absence of typical nemaline-rod histology. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Mathias SD, Chren MM, Crosby RD, Colwell HH, Yim YM, Reyes C, Chen DM, Fosko SW. Reliability and validity of the Advanced Basal Cell Carcinoma Index (aBCCdex). Br J Dermatol 2015; 173:713-9. [PMID: 25939524 DOI: 10.1111/bjd.13877] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/07/2015] [Indexed: 11/29/2022]
Abstract
BACKGROUND Patient-reported outcome (PRO) questionnaires were recently developed specifically for use with patients with advanced basal cell carcinoma (aBCC) and basal cell carcinoma naevus syndrome (BCCNS). OBJECTIVES To evaluate the measurement properties of PRO questionnaires for use in patients with aBCC or BCCNS. METHODS In total 129 patients from 10 clinical sites in the U.S.A. and the BCCNS Support Network completed the two newly developed questionnaires multiple times over 3 months. Patients also completed the Skindex-16 and the 12-Item Short-Form Health Survey as collateral measures. Psychometric properties of the questionnaires were evaluated, including internal consistency and test-retest reliability, construct and known-groups validity, and responsiveness. RESULTS Based on the results of exploratory factor analysis and clinical input, the two newly developed questionnaires were combined into a single questionnaire, called the aBCCdex, which is relevant for patients with both aBCC and BCCNS. The internal consistency reliability was acceptable, and all aBCCdex scale scores correlated significantly with conceptually similar scales. When divided into groups that differed based on scores from collateral measures, aBCCdex scale scores differentiated between groups (known-groups validity) and were responsive to change. CONCLUSIONS The aBCCdex is a brief and comprehensive questionnaire appropriate for use with patients with aBCC and BCCNS. Its reliability and validity have been confirmed. Further research is necessary to estimate the minimally important difference in a larger patient population.
Collapse
Affiliation(s)
- S D Mathias
- Health Outcomes Solutions, 2351 Via Tuscany, Winter Park, FL, 32789, U.S.A
| | - M M Chren
- Department of Dermatology, University of California San Francisco, San Francisco, CA, U.S.A
| | - R D Crosby
- Health Outcomes Solutions, Neuropsychiatric Research Institute, and University of North Dakota School of Medicine and Health Sciences, Fargo, ND, U.S.A
| | - H H Colwell
- Health Outcomes Solutions, 2351 Via Tuscany, Winter Park, FL, 32789, U.S.A
| | - Y M Yim
- Genentech, San Francisco, CA, U.S.A
| | - C Reyes
- Genentech, San Francisco, CA, U.S.A
| | - D M Chen
- Genentech, San Francisco, CA, U.S.A
| | - S W Fosko
- Departments of Dermatology, Internal Medicine, Head and Neck Surgery-Otolaryngology and Ophthalmology, Saint Louis University Cancer Center, Saint Louis University School of Medicine, St Louis, MO, U.S.A
| |
Collapse
|
45
|
Leach M, Donkervoort S, Simpson K, Tesi-Rocha A, Avery R, Dastgir J, Reyes C, Hu Y, Winder T, Bönnemann C. G.P.152. Neuromuscul Disord 2014. [DOI: 10.1016/j.nmd.2014.06.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
46
|
Gibney G, Gauthier G, Ayas C, Galebach P, Wu E, Yim Y, Abhyankar S, Reyes C, Guerin A. Predictors of Treatment (Tx) Response and Progression in Braf V600E Metastatic Melanoma (Mm) Patients (Pts) with Brain Metastases (Bm) Receiving Vemurafenib (Vem) in a Real-World Setting. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu344.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Reyes C, Gazauskas G, Veentra D. Cost-Effectiveness of Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu341.9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Reyes C, Estrada P, Nogués X, Orozco P, Cooper C, Díez-Pérez A, Formiga F, González-Macías J, Prieto-Alhambra D. The impact of common co-morbidities (as measured using the Charlson index) on hip fracture risk in elderly men: a population-based cohort study. Osteoporos Int 2014; 25:1751-8. [PMID: 24676845 DOI: 10.1007/s00198-014-2682-9] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2013] [Accepted: 03/10/2014] [Indexed: 10/25/2022]
Abstract
UNLABELLED We used a large population-based health care database to determine the impact of common co-morbidities on hip fracture risk amongst elderly men. We demonstrated that diabetes, chronic obstructive pulmonary disease, renal failure, HIV infection, dementia, and cerebrovascular disease are independent predictors of hip fracture, as is a Charlson score of ≥ 3. INTRODUCTION Risk factors for hip fractures in men are still unclear. We aimed to identify common co-morbidities (amongst those in the Charlson index) that confer an increased risk of hip fracture amongst elderly men. METHODS We conducted a population-based cohort study using data from the SIDIAP (Q) database. SIDIAP(Q) contains primary care and hospital inpatient records of a representative 30% of the population of Catalonia, Spain (>2 million people). All men aged ≥ 65 years registered on 1 January 2007 were followed up until 31 December 2009. Both exposure (co-morbidities in the Charlson index) and outcome (incident hip fractures) were ascertained using ICD codes. Poisson regression models were fitted to estimate the effect of (1) each individual co-morbidity and (2) the composite Charlson index score, on hip fracture risk, after adjustment for age, body mass index, smoking, alcohol drinking, and use of oral glucocorticoids. RESULTS We observed 186,171 men for a median (inter-quartile range) of 2.99 (2.37-2.99) years. In this time, 1,718 (0.92%) participants had a hip fracture. The following co-morbidities were independently associated with hip fractures: diabetes mellitus, chronic obstructive pulmonary disease (COPD), renal failure, HIV infection, dementia, and cerebrovascular disease. A Charlson score of ≥ 3 conferred an increased hip fracture risk. CONCLUSION Common co-morbidities including diabetes, COPD, cerebrovascular disease, renal failure, and HIV infection are independently associated with an increased risk of hip fracture in elderly men. A Charlson score of 3 or more is associated with a 50% higher risk of hip fracture in this population.
Collapse
Affiliation(s)
- C Reyes
- Primary Health Care Center, Eap Sardenya-Biomedical Resarch Institute Sant Pau (IIB Sant Pau), c/Sardenya 466, Barcelona, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, Mauborgne C, Rouleau E, Reyes C, Henry E, Leroy Q, Gestraud P, La Rosa P, Escalup L, Mitry E, Trédan O, Delord JP, Campone M, Goncalves A, Isambert N, Gavoille C, Kamal M. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br J Cancer 2014; 111:17-24. [PMID: 24762958 PMCID: PMC4090722 DOI: 10.1038/bjc.2014.211] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2014] [Revised: 03/24/2014] [Accepted: 03/27/2014] [Indexed: 12/24/2022] Open
Abstract
Background: The SHIVA trial is a multicentric randomised proof-of-concept phase II trial comparing molecularly targeted therapy based on tumour molecular profiling vs conventional therapy in patients with any type of refractory cancer. Results of the feasibility study on the first 100 enrolled patients are presented. Methods: Adult patients with any type of metastatic cancer who failed standard therapy were eligible for the study. The molecular profile was performed on a mandatory biopsy, and included mutations and gene copy number alteration analyses using high-throughput technologies, as well as the determination of oestrogen, progesterone, and androgen receptors by immunohistochemistry (IHC). Results: Biopsy was safely performed in 95 of the first 100 included patients. Median time between the biopsy and the therapeutic decision taken during a weekly molecular biology board was 26 days. Mutations, gene copy number alterations, and IHC analyses were successful in 63 (66%), 65 (68%), and 87 (92%) patients, respectively. A druggable molecular abnormality was present in 38 patients (40%). Conclusions: The establishment of a comprehensive tumour molecular profile was safe, feasible, and compatible with clinical practice in refractory cancer patients.
Collapse
Affiliation(s)
- C Le Tourneau
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France [3] Institut Curie, Saint-Cloud, France
| | - X Paoletti
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | - N Servant
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | | | | | | | | | | | - J Romejon
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | | | | | - P Huppe
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | | | - F Mulot
- Institut Curie, Paris, France
| | | | - J Wong
- Institut Curie, Paris, France
| | | | | | - C Reyes
- Institut Curie, Paris, France
| | - E Henry
- Institut Curie, Paris, France
| | - Q Leroy
- Institut Curie, Paris, France
| | - P Gestraud
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | - P La Rosa
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | | | - E Mitry
- Institut Curie, Saint-Cloud, France
| | - O Trédan
- Centre Léon Bérard, Lyon, France
| | - J-P Delord
- Institut Claudius Régaud, Toulouse, France
| | - M Campone
- Centre René Gauducheau, Nantes, France
| | | | - N Isambert
- Centre Georges-François Leclerc, Dijon, France
| | | | - M Kamal
- Institut Curie, Paris, France
| |
Collapse
|
50
|
Montenegro S, Villalobos P, De La Barra T, Reyes C, Pineda S, Palma C, Delgado C, Mucientes F. Frequency of human papilloma virus (HPV) and p16 expression in patients with head and neck squamous cell carcinoma (HNSCC) in Concepcion, Chile. Int J Infect Dis 2014. [DOI: 10.1016/j.ijid.2014.03.1078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|